<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">56630</article-id><article-id pub-id-type="doi">10.7554/eLife.56630</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction related to psychiatric disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-93551"><name><surname>Wong</surname><given-names>Helen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3927-8953</contrib-id><email>hw460@nyu.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-93550"><name><surname>Levenga</surname><given-names>Josien</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9971-6337</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-93554"><name><surname>LaPlante</surname><given-names>Lauren</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-93553"><name><surname>Keller</surname><given-names>Bailey</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178997"><name><surname>Cooper-Sansone</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178996"><name><surname>Borski</surname><given-names>Curtis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-93552"><name><surname>Milstead</surname><given-names>Ryan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3333-853X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211462"><name><surname>Ehringer</surname><given-names>Marissa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-66789"><name><surname>Hoeffer</surname><given-names>Charles</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2036-0201</contrib-id><email>charles.hoeffer@colorado.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute for Behavioral Genetics, University of Colorado</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Linda Crnic Institute, Anschutz Medical Center</institution><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Integrative Physiology, University of Colorado</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lobo</surname><given-names>Mary Kay</given-names></name><role>Reviewing Editor</role><aff><institution>University of Maryland</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Wassum</surname><given-names>Kate M</given-names></name><role>Senior Editor</role><aff><institution>University of California, Los Angeles</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>16</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e56630</elocation-id><history><date date-type="received" iso-8601-date="2020-03-04"><day>04</day><month>03</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-15"><day>15</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Wong et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wong et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-56630-v2.pdf"/><abstract><p>AKT is implicated in neurological disorders. AKT has three isoforms, AKT1/AKT2/AKT3, with brain cell type-specific expression that may differentially influence behavior. Therefore, we examined single <italic>Akt</italic> isoform, conditional brain-specific <italic>Akt1</italic>, and double <italic>Akt1/3</italic> mutant mice in behaviors relevant to neuropsychiatric disorders. Because sex is a determinant of these disorders but poorly understood, sex was an experimental variable in our design. Our studies revealed AKT isoform- and sex-specific effects on anxiety, spatial and contextual memory, and fear extinction. In <italic>Akt1</italic> mutant males, viral-mediated AKT1 restoration in the prefrontal cortex rescued extinction phenotypes. We identified a novel role for AKT2 and overlapping roles for AKT1 and AKT3 in long-term memory. Finally, we found that sex-specific behavior effects were not mediated by AKT expression or activation differences between sexes. These results highlight sex as a biological variable and isoform- or cell type-specific AKT signaling as potential targets for improving treatment of neuropsychiatric disorders.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>extinction</kwd><kwd>hippocampus</kwd><kwd>prefrontal cortex</kwd><kwd>isoform</kwd><kwd>associative memory</kwd><kwd>spatial learning</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>NS086933</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Helen</given-names></name><name><surname>Levenga</surname><given-names>Josien</given-names></name><name><surname>LaPlante</surname><given-names>Lauren</given-names></name><name><surname>Keller</surname><given-names>Bailey</given-names></name><name><surname>Cooper-Sansone</surname><given-names>Andrew</given-names></name><name><surname>Borski</surname><given-names>Curtis</given-names></name><name><surname>Milstead</surname><given-names>Ryan</given-names></name><name><surname>Hoeffer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>MH016880</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Helen</given-names></name><name><surname>Hoeffer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007353</institution-id><institution>Jerome Lejeune Foundation</institution></institution-wrap></funding-source><award-id>1805</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Helen</given-names></name><name><surname>Cooper-Sansone</surname><given-names>Andrew</given-names></name><name><surname>Hoeffer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG 064465</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Helen</given-names></name><name><surname>LaPlante</surname><given-names>Lauren</given-names></name><name><surname>Hoeffer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG052371</award-id><principal-award-recipient><name><surname>Milstead</surname><given-names>Ryan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Murine behavioral testing and biochemical experiments reveal AKT isoform- and sex-dependent mechanisms regulating affective behavior, memory formation, and extinction.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and anxiety, are important public health burdens with large societal and economic costs (<xref ref-type="bibr" rid="bib98">Wittchen et al., 2011</xref>; <xref ref-type="bibr" rid="bib94">Vigo et al., 2016</xref>). Genetics is known to play a significant role in the manifestation of psychiatric illnesses (<xref ref-type="bibr" rid="bib90">Sullivan et al., 2003</xref>; <xref ref-type="bibr" rid="bib87">Schumacher et al., 2011</xref>; <xref ref-type="bibr" rid="bib71">Musci et al., 2019</xref>). Numerous studies in humans and experimental model systems have identified genetic variations that can promote abnormal neural function underlying the occurrence of these disorders (<xref ref-type="bibr" rid="bib83">Renoir, 2014</xref>). Detailed molecular studies have also led to the development of many pharmacological treatments for psychiatric illnesses. However, the effectiveness of available therapies is still limited and many patients remain untreated (<xref ref-type="bibr" rid="bib39">Gould et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Duman and Voleti, 2012</xref>). This may be due in part to lack of information about the specificity of neuromolecular signaling pathways involved in the manifestation of individual behaviors and processes associated with the symptomology of psychiatric disorders as well the specific signaling effects within different neural cell types and those impacted by sex. Consequently, further identification of critical signaling pathways are necessary for developing new therapeutic targets and improving efficacy of existing ones.</p><p>The protein kinase B (PKB/AKT) family of serine/threonine kinases is involved in numerous neuromolecular signaling processes (<xref ref-type="bibr" rid="bib52">Kandel and Hay, 1999</xref>; <xref ref-type="bibr" rid="bib37">Franke, 2008</xref>) and has been implicated in neurological and psychiatric disorders (<xref ref-type="bibr" rid="bib85">Saudou et al., 1998</xref>; <xref ref-type="bibr" rid="bib48">Ikeda et al., 2004</xref>; <xref ref-type="bibr" rid="bib40">Griffin et al., 2005</xref>). For example, <italic>Akt1</italic> haplotypes have been identified in schizophrenic patients (<xref ref-type="bibr" rid="bib33">Emamian et al., 2004</xref>; <xref ref-type="bibr" rid="bib48">Ikeda et al., 2004</xref>; <xref ref-type="bibr" rid="bib88">Schwab et al., 2005</xref>; <xref ref-type="bibr" rid="bib101">Xu et al., 2007</xref>). Additionally, antidepressants, antipsychotics, and mood stabilizers are known to modify AKT activity (<xref ref-type="bibr" rid="bib61">Li et al., 2004</xref>; <xref ref-type="bibr" rid="bib58">Krishnan et al., 2008</xref>; <xref ref-type="bibr" rid="bib12">Beaulieu et al., 2009</xref>; <xref ref-type="bibr" rid="bib63">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Park et al., 2014</xref>). AKT is expressed as three isoforms termed AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ in the brain. Each isoform shows significant homology with one another and across species, being highly conserved in both humans and mice. Despite this homology, the isoforms exhibit different expression patterns in the brain and regulate the expression of synaptic plasticity differently (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). Therefore, it is possible that the different isoforms also contribute differentially to cognitive processes affected in schizophrenia and affective disorders, such as memory formation and extinction. Unfortunately, the overwhelming number of human and animal studies have investigated AKT from a general perspective not delineating between isoforms. A few single AKT isoform studies have been performed with conflicting results (<xref ref-type="bibr" rid="bib19">Chang et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Wang et al., 2017</xref>). Additionally, no study to date has simultaneously examined AKT isoform deficiencies using a comprehensive battery of behavior tests. Finally, the few studies that have examined single AKT isoforms have ignored sex as a variable and, therefore, may have missed important sex-linked effects.</p><p>To address these gaps in our knowledge of AKT signaling related to psychiatric disorders, we selectively removed AKT isoforms from the mouse brain using complementary genetic approaches, generating mutant mice with single-isoform deficiencies in AKT1, AKT2, or AKT3; selective loss of AKT1 in forebrain excitatory neurons; or double loss of AKT1 and AKT3 isoforms. With these mice, we performed murine behavioral assays that are models for affective behavior, spatial learning and memory, and associative fear memory and extinction. The behavioral results provide multiple lines of evidence demonstrating specific and overlapping roles for AKT isoforms in the activity of neural circuits that may model brain processes impacted in neuropsychiatric disorders. On balance, AKT1 exerts the strongest individual isoform effects on cognition and behavior, influencing males selectively in many of the tests we performed. Like AKT1, AKT2 affects anxiety-like behavior in a sex-specific fashion and impacts contextual memory. AKT3 exerted no effects on its own but in the background of AKT1 deficiency, enhanced deficits we observed in <italic>Akt1</italic> mutants. Therefore, this study provides novel evidence demonstrating AKT isoform-specific regulation of neural function in a sex-specific fashion. Combined with the fact that AKT isoforms are expressed in a cell type-specific fashion, these findings improve understanding of how AKT activity is specifically involved in distinct behaviors and neurobiological processes relevant to diagnoses and therapies directed against AKT signaling pathways for treating psychiatric disorders.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Akt</italic> deficiency alters anxiety-like behavior in an isoform- and sex-specific manner</title><p>To investigate the isoform-specific contributions of AKT and any sex-specific effects on cognitive processes, we began all behavioral studies of <italic>Akt</italic> mutant mice with a basic locomotor assessment using the open field arena (OFA) test. Besides locomotor activity, OFA assesses anxiety-like behavior by measuring time spent exploring the periphery or exposed center of the arena (<xref ref-type="bibr" rid="bib16">Bouwknecht and Paylor, 2008</xref>). OFA testing revealed that male <italic>Akt1</italic> KO mice spend significantly less time exploring the center compared with wild-type (WT) littermate controls (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; t(42)=4.789, p&lt;0.001), indicating increased anxiety-like behavior, which was not due to differences in overall movement (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In contrast, female <italic>Akt1</italic> WT and KO mice were indistinguishable (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). No genotype effects were observed in <italic>Akt2</italic> or <italic>Akt3</italic> mutants for both sexes (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Akt</italic> deficiency affects the expression of anxiety-related behavior in an isoform- and sex-specific fashion.</title><p>Male and female mice with single-isoform deletions of <italic>Akt1, Akt2,</italic> or <italic>Akt3</italic> were assessed for anxiety-related behaviors in the open field arena (OFA) and elevated plus maze (EPM) tests. (<bold>A–B</bold>) OFA activity shown as percent time spent exploring the center zone out of total arena time in <italic>Akt</italic> mutant (<bold>A</bold>) male and (<bold>B</bold>) female mice. <italic>Akt1</italic> KO male mice show reduced center time compared to their WT controls. (<bold>C–D</bold>) EPM activity shown as percent time spent in the open arms out of total maze time in <italic>Akt</italic> mutant (<bold>C</bold>) male and (<bold>D</bold>) female mice. <italic>Akt1</italic> KO and <italic>Akt2</italic> KO male mice show reduced open arm time compared with their respective WT controls. Differences in OFA center or EPM open arm times are not explained by locomotor alterations between KO and WT mice. No differences between female KO and WT mice were observed. *p&lt;0.05. N = <italic>Akt1</italic> (WT-M = 22, KO-M = 22, WT-F = 16, KO-F = 13); <italic>Akt2</italic> (WT-M = 13–14, KO-M = 15–16, WT-F = 12–13, KO-F = 11); <italic>Akt3</italic> (WT-M = 19, KO-M = 23, WT-F = 17–18, KO-F = 18).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Figure 1 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Schematic representation of the experimental timeline.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig1-figsupp1-v2.tif"/></fig></fig-group><p>To complement our OFA studies, we also performed elevated plus maze (EPM) testing, which examines anxiety-like behavior and exploratory drive in rodents (<xref ref-type="bibr" rid="bib16">Bouwknecht and Paylor, 2008</xref>). Time spent exploring the EPM open (exposed) arms is a measure of anxiolytic-like behavior. Consistent with increased anxiety-like behavior, <italic>Akt1</italic> mutants also displayed a male-specific reduction in open arm time compared with controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; t(42)=2.156, p=0.037), which was not due to differences in distance moved (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). EPM testing also revealed decreased open arm time in <italic>Akt2</italic> mutant males compared with WT controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; t(28)=2.651, p=0.013) that was not due to differences in overall movement (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), indicating increased anxiety-like behavior. In contrast, <italic>Akt1</italic> or <italic>Akt2</italic> deletion had no effect on female mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) while <italic>Akt3</italic> deletion had no effect on either sex (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>) in the EPM. Together these OFA and EPM data demonstrate that <italic>Akt1</italic> and <italic>Akt2</italic> deficiency affect the expression of anxiety-related behaviors in a sex-specific fashion.</p></sec><sec id="s2-2"><title>AKT1 deficiency leads to a mild spatial memory impairment</title><p>We next examined isoform-specific contributions of <italic>Akt</italic> to spatial learning and memory using the Morris Water Maze (MWM) (<xref ref-type="bibr" rid="bib70">Morris, 1984</xref>). In this assay, mice are trained to find a hidden escape platform in a pool of water using visual cues. Spatial learning is measured by the escape latency curve over the training period. Cognitive flexibility also can be tested in this assay with reversal training, in which mice are re-trained to find the platform in the quadrant of the maze opposite the original training location. Finally, intact vision, required for this task, is assessed in a visible platform training component. No latency differences in each training component were detected for any <italic>Akt</italic> mutants compared to WT controls (<xref ref-type="fig" rid="fig2">Figure 2</xref>), indicating normal spatial learning, reversal learning, and visual acuity. After MWM training, spatial memory efficacy is evaluated using a probe test in which the escape platform is removed, and time spent in the target quadrant where the platform had been located and frequency of crossing the specific platform location are measured. We found no differences in target quadrant time between <italic>Akt1</italic> KO and WT mice (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>; males t(16)=1.187, p&gt;0.05; females t(16)=-.489, p&gt;0.05), but <italic>Akt1</italic> KO males displayed reduced target platform crossings compared with controls (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; t(16)=2.389, p=0.030), indicating a sex-specific deficit in more precise spatial memory. Probe tests revealed no differences in <italic>Akt2</italic> KO (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>) or <italic>Akt3</italic> KO mice (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>). Combined, these data suggest a subtle requirement for <italic>Akt1</italic> in males during spatial memory formation.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Akt</italic> deficiency affects spatial memory formation in an isoform- and sex-specific fashion.</title><p>Spatial learning and memory were assessed using the Morris Water Maze (MWM) in male and female mice with single-isoform deletions of <italic>Akt1, Akt2,</italic> or <italic>Akt3. Left graph</italic>: Learning measured by latency of mice to escape the MWM during training to locate a hidden escape platform (days 1–8), reversal training to locate the hidden escape platform moved to the opposite quadrant (days 9–11), and visible platform training to locate the escape platform marked by a visual cue (days 12–13). Memory measured by percent time spent in the target quadrant where mice were trained to locate the hidden escape (<italic>left bar graph</italic>) and number of platform location crossings in the target quadrant (<italic>right bar graph</italic>) during a probe test. MWM performance in (<bold>A</bold>) <italic>Akt1</italic> KO male, (<bold>B</bold>) <italic>Akt1</italic> KO female, (<bold>C</bold>) <italic>Akt2</italic> KO male, (<bold>D</bold>) <italic>Akt2</italic> KO female, (<bold>E</bold>) <italic>Akt3</italic> KO male, and (<bold>F</bold>) <italic>Akt3</italic> KO female mice. <italic>Akt1</italic> KO male mice showed a significant reduction in platform crossings compared with WT controls during the probe test. No other differences were detected between <italic>Akt</italic> isoform KO and WT mice. *p&lt;0.05. N = <italic>Akt1</italic> (WT-M = 9 KO-M = 9, WT-F = 9, KO-F = 9); <italic>Akt2</italic> (WT-M = 9, KO-M = 11, WT-F = 11, KO-F = 9); <italic>Akt3</italic> (WT-M = 10, KO-M = 11, WT-F = 10, KO-F = 9).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Figure 2 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title><italic>Akt</italic> deficiency impacts conditioned fear in an isoform- and sex-specific manner</title><p>To identify further isoform-specific contributions of AKT and sex-specific effects on cognitive processes, we examined associative fear long-term memory (LTM) in <italic>Akt</italic> mutant mice conditioned to associate an aversive foot-shock to an initially neutral tone. We found no effects on training performance or contextual and cued LTM evaluated 24 hr post-training in <italic>Akt1</italic> KO mice (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). For <italic>Akt2</italic> KO mice, contextual LTM was impaired relative to WT littermates in males (<xref ref-type="fig" rid="fig3">Figure 3C</xref>; t(28)=-2.474, p=0.020) but not females (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). In <italic>Akt3</italic> KO mice, we detected no fear conditioning effects (<xref ref-type="fig" rid="fig3">Figure 3E,F</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Single <italic>Akt</italic> isoform deficiency does not impact cued fear LTM but <italic>Akt2</italic> deficiency affects contextual fear LTM in males.</title><p>Associative fear conditioning acquisition and long-term memory (LTM) in <italic>Akt</italic> isoform mutant male and female mice shown as percent time spent freezing. In training, freezing behavior was assessed during the baseline (pre) and 30 s after the first (CS1) and second (CS2) CS-US presentations. Contextual and cued LTM were assessed 24–25 hr after training by measuring freezing behavior during the entire test for contextual LTM and during the baseline (pre) and CS presentations (CS1, CS2) in the cued LTM test. Performance of (<bold>A</bold>) <italic>Akt1</italic> KO male, (<bold>B</bold>) <italic>Akt1</italic> KO female, (<bold>C</bold>) <italic>Akt2</italic> KO male, (<bold>D</bold>) <italic>Akt2</italic> KO female, (<bold>E</bold>) <italic>Akt3</italic> KO male, and (<bold>F</bold>) <italic>Akt3</italic> KO female mice. <italic>Akt2</italic> KO male mice showed impaired contextual LTM compared with WT controls. No other significant differences were detected between <italic>Akt</italic> isoform KO and WT mice. *p&lt;0.05. N = <italic>Akt1</italic> (WT-M = 16–17, KO-M = 13–15, WT-F = 10, KO-F = 10); <italic>Akt2</italic> (WT-M = 14, KO-M = 14–16, WT-F = 10–11, KO-F = 10); <italic>Akt3</italic> (WT-M = 18, KO-M = 18–20, WT-F = 17, KO-F = 16–17).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Figure 3 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig3-v2.tif"/></fig><p>Because <italic>AKT</italic> mutations and single nucleotide polymorphisms (SNP)s have been linked to psychiatric disorders like schizophrenia (<xref ref-type="bibr" rid="bib33">Emamian et al., 2004</xref>; <xref ref-type="bibr" rid="bib48">Ikeda et al., 2004</xref>; <xref ref-type="bibr" rid="bib88">Schwab et al., 2005</xref>; <xref ref-type="bibr" rid="bib101">Xu et al., 2007</xref>) and extinction is altered in the disorder (<xref ref-type="bibr" rid="bib22">Craske et al., 2018</xref>), we also examined extinction learning in <italic>Akt</italic> isoform mutants after fear conditioning. Interestingly, <italic>Akt1</italic> KO mice showed a male-specific enhancement in extinction learning compared with WT controls (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>; males F(1,30)=8.571, p=0.006). No extinction acquisition differences were observed in <italic>Akt2</italic> KO (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>) or <italic>Akt3</italic> KO (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>) mice. To determine the efficacy of extinction training in <italic>Akt</italic> mutant mice, we tested the resulting expression of cued fear memory. Consistent with their more rapid extinction learning, extinction LTM was enhanced specifically in <italic>Akt1</italic> KO males compared with WT controls (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; F(1,30)=9.121, p=0.005). When we tested renewal of extinguished fear by re-exposing mice to the CS in the original training context, <italic>Akt1</italic> KO male mice also showed reduced renewal relative to WT controls (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; F(1,30)=7.187, p=0.012). With <italic>Akt2</italic> KO mice, we detected no differences in extinction LTM from WT controls (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>), but KO males showed enhanced fear renewal (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; F(1,26)=5.969, p=0.022). <italic>Akt3</italic> KO mice showed no differences from WT controls in extinction LTM or renewal (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>). These data support a role for <italic>Akt1</italic> and <italic>Akt2</italic> in associative fear memory processes of males.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>AKT1 deficiency enhances fear extinction learning and AKT2 removal enhances fear renewal.</title><p>Extinction training to the CS was performed over three days (D1–D3) with 20 CS presentations each day. Extinction learning in mice measured as percent freezing during the baseline period prior to the first CS (pre) and during each CS presentation shown as average percent freezing in 4 blocks of 5 CS presentations each for every day of training. Efficacy of extinction learning assessed by testing extinction LTM (ext LTM) and renewal of extinguished cued LTM. Ext LTM measured as percent freezing to 2 CS presentations in a novel context 24 hr after completion of extinction training. Renewal measured as percent freezing to 2 CS presentations in the original training context 10 d after ext LTM testing. Performance of (<bold>A</bold>) <italic>Akt1</italic> KO male, (<bold>B</bold>) <italic>Akt1</italic> KO female, (<bold>C</bold>) <italic>Akt2</italic> KO male, (<bold>D</bold>) <italic>Akt2</italic> KO female, (<bold>E</bold>) <italic>Akt3</italic> KO male, and (<bold>F</bold>) <italic>Akt3</italic> KO female. <italic>Akt1</italic> KO males showed faster rates of extinction compared with controls while <italic>Akt2</italic> KO males showed increased renewal freezing compared with controls. No other significant differences were detected between <italic>Akt</italic> isoform KO and WT mice. *p&lt;0.05. N = <italic>Akt1</italic> (WT-M = 17, KO-M = 15, WT-F = 10, KO-F = 10); <italic>Akt2</italic> (WT-M = 13–14, KO-M = 15–16, WT-F = 9, KO-F = 9); <italic>Akt3</italic> (WT-M = 18, KO-M = 20, WT-F = 15–17, KO-F = 15–16).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Figure 4 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig4-v2.tif"/></fig></sec><sec id="s2-4"><title>Restoring AKT1 expression in the PFC rescues fear extinction processes in <italic>Akt1</italic> KO males</title><p>Because extinction memory relies on the prefrontal cortex (PFC) for normal display (<xref ref-type="bibr" rid="bib21">Courtney et al., 1998</xref>; <xref ref-type="bibr" rid="bib34">Fallgatter, 2001</xref>; <xref ref-type="bibr" rid="bib17">Bussey et al., 2012</xref>), we next tested if restoring AKT1 activity in the PFC might rescue the observed extinction effects in male <italic>Akt1</italic> KO mice (<xref ref-type="fig" rid="fig4">Figure 4</xref>). To do this, we injected the PFC of male WT and <italic>Akt1</italic> KO mice with AAV vectors to express either AKT1-GFP or Cre-GFP as a sham control (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We confirmed AAV expression in both the prelimbic (PL) and infralimbic (IL) regions of the PFC (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Furthermore, we confirmed that expression of AKT1 in the PFC of <italic>Akt1</italic> KO males (<italic>Akt1</italic> KO+<italic>AKT1</italic><sub>PFC</sub>) is restored in neurons (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), both excitatory and inhibitory neurons (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). We found no difference in conditioned fear learning or contextual and cued 24 hr memory in <italic>Akt1</italic> KO+<italic>AKT1</italic><sub>PFC</sub> mice compared to sham-treated WT and KO males (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, we found a significant effect on extinction learning (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; F(2,34)=5.400, p=0.009). In agreement with our previous experiment (<xref ref-type="fig" rid="fig4">Figure 4</xref>), <italic>Akt1</italic> KO-sham mice showed enhanced extinction learning compared with WT-sham mice (p=0.009). <italic>Akt1</italic> KO+<italic>AKT1</italic><sub>PFC</sub> males showed a significant difference in extinction learning from <italic>Akt1</italic> KO-sham mice (p=0.047) but not from WT-sham mice (p=0.875), consistent with the idea that PFC AKT1 activity underlies the extinction effects we observed in <italic>Akt1</italic> KO mice. We also found a significant difference in extinction LTM between <italic>Akt1</italic> KO-sham and WT-sham groups (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; F(2,34)=4.388, p=0.020, post-hoc comparison p=0.035) but no significant difference between WT-sham and <italic>Akt1</italic> KO+<italic>AKT1</italic><sub>PFC</sub> groups (post-hoc comparison p=0.985), supporting the notion that PFC-expressed AKT1 rescued <italic>Akt1</italic> KO effects on extinction LTM. Finally, we examined extinction renewal following PFC AKT1 expression. We did not observe a significant difference between WT-sham and <italic>Akt1</italic> KO+<italic>AKT1</italic><sub>PFC</sub> groups (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; F(2,29)=1.018, p=0.374, post-hoc comparison p=0.605). Unexpectedly, we also did not observe a significant difference between WT-sham and <italic>Akt1</italic> KO-sham groups (post-hoc comparison p=0.375), as we did with WT and <italic>Akt1</italic> KO mice in the previous experiment (<xref ref-type="fig" rid="fig4">Figure 4</xref>). However, the combined data support that idea that AKT1-mediated PFC function underlies effects of <italic>Akt1</italic> deficiency on the expression of extinction-related behaviors.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Restoration of AKT1 expression in the PFC normalizes extinction learning and LTM in <italic>Akt1</italic> KO males.</title><p>(<bold>A</bold>) Experimental design to test the function of AKT1 in the PFC. AKT1 expression was restored using AAV-mediated pan-neuronal (hSyn) co-expression of AKT1 and green fluorescent protein (GFP) in the PFC of <italic>Akt1</italic> KO male mice (KO+<italic>AKT1</italic><sub>PFC</sub>). Sham surgeries were performed on <italic>Akt1</italic> KO and WT males using hSyn-driven expression of GFP-tagged Cre recombinase (Cre-GFP) to generate control groups (WT-sham, KO-sham). Mice were injected with AAV in the PL at 1.98 mm AP and then tested on associative fear conditioning and extinction beginning 21 days post-injection. (<bold>B</bold>) <italic>Left:</italic> Schematic of AAV expression spread (green areas) in the mouse PFC at 1.70 mm AP overlaid for six subjects (N = 2/group). <italic>Right</italic>: Representative image of AAV expression. Green, GFP; blue, Hoechst. Scale bar, 500 µm. (<bold>C</bold>) Higher magnification of PFC corresponding to orange boxed area in (<bold>B</bold>) right image. Staining for AKT1 (red) in the PFC of KO+<italic>AKT1</italic><sub>PFC</sub> mice confirms that AKT1 expression is restored in neurons and colocalizes with GFP (AAV-infected cells). Scale bars, 40 µm. (<bold>D</bold>) Sham surgery and AKT1 restoration in <italic>Akt1</italic> KO mice did not affect fear acquisition or 24 hr contextual and cued LTM. (<bold>E</bold>) Extinction learning and LTM were restored to WT levels in KO+<italic>AKT1</italic><sub>PFC</sub> mice but not renewal. KO-sham mice displayed reduced freezing compared with either WT-sham or KO+<italic>AKT1</italic><sub>PFC</sub> groups. *p&lt;0.05. N(WT-sham, KO-sham, KO+<italic>AKT1</italic><sub>PFC</sub>)=15,11,11 except for renewal, due to loss of animals between extinction and renewal test phases: N = 13,11,8. Schematics of the mouse brain are guided by <xref ref-type="bibr" rid="bib38">Franklin and Paxinos, 2007</xref>. PFC, prefrontal cortex; PL, prelimbic cortex; IL, infralimbic cortex; CC, corpus callosum.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Figure 5 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Restoration of neuronal AKT1 expression in the PFC of <italic>Akt1</italic> KO male mice.</title><p>(<bold>A</bold>) Representative image of AKT1 and green fluorescent protein (GFP) co-expression in the PFC of <italic>Akt1</italic> KO male mice injected with AAV-hSyn::AKT1-GFP. Staining for AKT1 (red) confirms AKT1 expression that colocalizes with GFP (green). Scale bar, 200 µm. (<bold>B</bold>) Higher magnification images of the white boxed area in (<bold>A</bold>) shows AAV expression in neurons. The pan-neuronal human synapsin I (hSyn) promoter in the AAV construct drives AKT1 and GFP expression in both excitatory and inhibitory neurons. Co-staining for the interneuronal marker parvalbumin (PV, white) confirms AAV expression in inhibitory neurons (white arrows). Yellow arrows, putative excitatory neurons (PV-negative). Scale bars, 40 µm. PFC, prefrontal cortex; PL, prelimbic cortex; IL, infralimbic cortex; CC, corpus callosum.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Restricted <italic>Akt1</italic> deficiency affects contextual fear memory but not fear extinction</title><p>To determine if systemic or developmental <italic>Akt1</italic> deficiency led to the phenotypes we observed in <italic>Akt1</italic> KO males, we generated conditional KO mice with Cre-mediated <italic>Akt1</italic> removal (<italic>Akt1 c</italic>KO) from excitatory neurons of the forebrain, including the amygdala and PFC (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) and hippocampus (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>), late in development (<xref ref-type="bibr" rid="bib42">Hoeffer et al., 2008</xref>). We found no differences in OFA center time (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) or EPM open arm time (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) between male <italic>Akt1</italic> cKO and WT mice, suggesting AKT1 activity in forebrain excitatory neurons or late development is not required for normal anxiogenic-like responses. Additionally, <italic>Akt1 c</italic>KO males performed similarly in the MWM to WT controls (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), suggesting AKT1 activity in forebrain excitatory neurons or late development is not required for spatial memory as well. Conditional <italic>Akt1</italic> removal also had no effect on associative fear learning and cued LTM (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) or on extinction learning and LTM (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), although there was a trend for enhanced fear renewal (<xref ref-type="fig" rid="fig6">Figure 6E</xref>; F(1, 22)=3.105, p=0.092). Interestingly, contextual LTM was impaired in <italic>Akt1 c</italic>KO males (<xref ref-type="fig" rid="fig6">Figure 6D</xref>; t(22)=2.535, p=0.019), suggesting AKT1 activity in forebrain excitatory neurons or late development of male mice is required for contextual fear memory. Although we did observe some effect on memory formation, remarkably we did not identify a requirement for excitatory neuron AKT1 activity in the normal expression of many behaviors. Taken together with our results from restoring neuronal AKT1 expression in the PFC (<xref ref-type="fig" rid="fig5">Figure 5</xref>), these data suggest that AKT1 activity within interneurons is required for normal extinction learning.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Conditional <italic>Akt1</italic> deficiency in excitatory neurons impairs contextual fear LTM but does affect anxiety-related behaviors or fear extinction processes.</title><p>Behavior of conditional <italic>Akt1</italic> KO (<italic>Akt1</italic> cKO) male mice generated by removal of <italic>Akt1</italic> with a forebrain excitatory neuron-specific Cre driver in floxed <italic>Akt1</italic> mice. (<bold>A</bold>) OFA activity, measured as percent time spent exploring the center zone, and (<bold>B</bold>) EPM activity, measured as percent time spent in the open arms, were similar between <italic>Akt1</italic> cKO and WT mice. Distance moved during OFA or EPM assays also were similar between genotypes. N = 14 WT, 20 cKO. (<bold>C</bold>) <italic>Akt1</italic> cKO mice and WT controls showed similar latencies to escape the MWM during training, reversal, and visible platform phases and similar probe test performance measured as percent time spent and number of platform location crossings in the target quadrant. N = 8 WT, 8 cKO. (<bold>D</bold>) <italic>Akt1</italic> cKO mice showed impaired contextual fear LTM but no difference in fear learning or cued LTM compared with WT controls. N = 11 WT, 13 cKO. (<bold>E</bold>) No significant difference in extinction learning, extinction LTM (ext LTM) or renewal was seen between <italic>Akt1</italic> cKO and WT mice. N = 11 WT, 13 cKO. *p&lt;0.05.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Figure 6 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>AKT1 expression in conditional <italic>Akt1</italic> KO (<italic>Akt1</italic> cKO) male mice under the excitatory neuron-specific T29-1 <italic>Camk2α-</italic>Cre driver.</title><p>(<bold>A</bold>) Western blot analysis shows reduced AKT1 levels in the amygdala (amy) and prefrontal cortex (PFC) of <italic>Akt1</italic> cKO mice compared with WT controls while AKT3 levels are not affected. β-actin, loading control. N = 6/genotype. *p&lt;0.05. (<bold>B</bold>) Immunostaining shows AKT1 is normally expressed in both excitatory and inhibitory neurons, marked by NeuN, and confirms AKT1 removal in <italic>Akt1</italic> cKO mice from most neurons, putatively excitatory neurons (white arrows), in the amy and PFC. Inhibitory neurons marked by parvalbumin (PV, yellow arrows) show intact AKT1 expression in <italic>Akt1</italic> cKO mice. Arrowhead, putative inhibitory neuron of another subtype (PV-negative). Hoechst, nuclear stain. Scale bars: 200 μm (top row), 40 μm (below). (<bold>C</bold>) AKT3 is normally detected in excitatory neurons but not PV-positive neurons (yellow arrows) in hippocampal area CA1 and does not show a compensatory increase in expression in <italic>Akt1</italic> cKO mice. Scale bar, 40 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>AKT1 and AKT3 function may substitute for each other during memory processes</title><p>Because AKT1 and AKT3 are expressed in similar cell types in the brain (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>), they may provide compensatory activity in the absence of the other. To test this idea, we generated mice with conditional <italic>Akt1</italic> removal in the <italic>Akt3</italic> KO background (<italic>Akt1</italic> cKO <italic>Akt3</italic> KO) (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). When we assessed anxiety-like behavior in <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mice, we found no performance differences in the OFA (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) or EPM (<xref ref-type="fig" rid="fig7">Figure 7B</xref>) compared to WT controls for either sex. In the MWM, spatial learning was also indistinguishable between <italic>Akt1</italic> cKO <italic>Akt3</italic> KO and WT mice for both sexes (<xref ref-type="fig" rid="fig7">Figure 7C,D</xref>). However, <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mice did show significantly reduced target quadrant time and target platform crossings compared with WT littermates for both males (<xref ref-type="fig" rid="fig7">Figure 7C</xref>; quadrant time t(20)=2.172, p=0.042; crossings t(20)=3.406, p=0.003) and females (<xref ref-type="fig" rid="fig7">Figure 7D</xref>; quadrant time t(22)=3.262, p=0.004; crossings t(22)=2.283, p=0.032), indicating pronounced spatial memory deficits with simultaneous <italic>Akt1</italic> and <italic>Akt3</italic> removal. Similarly in associative fear conditioning, training performance of <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mice was normal but contextual LTM was impaired for both males (<xref ref-type="fig" rid="fig7">Figure 7E</xref>; t(20)=2.213, p=0.039) and females (<xref ref-type="fig" rid="fig7">Figure 7F</xref>; t(23)=2.250, p=0.034) compared with WT controls. Taken together with the results in single <italic>Akt</italic> isoform KO mice (<xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig3">3</xref>), these data suggest that AKT3 substitutes for AKT1 activity in female mice while AKT1 can substitute for AKT3 in both sexes during spatial memory tasks. Furthermore, these findings suggest all three AKT isoforms play a role in contextual fear memory of male mice. Interestingly, <italic>Akt1</italic> cKO <italic>Akt3</italic> KO males and females also showed deficits in cued LTM (<xref ref-type="fig" rid="fig7">Figure 7E,F</xref>; males F(1,20)=5.176, p=0.034; females F(1,22)=4.533, p=0.045), suggesting <italic>Akt1</italic> and <italic>Akt3</italic> can compensate for each other in cued fear memory in both sexes. These data strongly implicate AKT1 and AKT3 in providing overlapping function in the brain. Importantly, they suggest that female behavior and memory are in fact regulated by AKT1 activity but AKT3 can provide compensatory function in females not available in male mice.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Simultaneous removal of AKT1 and AKT3 isoforms from the brain promotes memory deficits in both male and female mice.</title><p>Male and female mice with conditional <italic>Akt1</italic> removal in the background of <italic>Akt3</italic> deficiency (<italic>Akt1</italic> cKO <italic>Akt3</italic> KO) were assessed in anxiety-related behavior, spatial memory, and associative fear memory tests. No differences were detected between <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mutant mice and WT controls for both sexes in (<bold>A</bold>) OFA activity, measured as percent time spent exploring the center zone, and (<bold>B</bold>) EPM activity, measured as percent time spent in the open arms. Distance moved during OFA or EPM assays were similar between genotypes for both sexes. N = 15 WT-M, 13 cKO/KO-M, 16 WT-F, 15 cKO/KO-F. (<bold>C</bold>) Male and (<bold>D</bold>) female <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mice had similar latencies to escape the MWM during training, reversal, and visible platform phases compared to their respective WT controls but showed significantly reduced target quadrant time and platform crossings. N = 13 WT-M, 9 cKO/KO-M, 12 WT-F, 12 cKO/KO-F. (<bold>E</bold>) Male and (<bold>F</bold>) female <italic>Akt1</italic> cKO <italic>Akt3</italic> KO mice displayed normal fear learning but impaired contextual and cued LTM compared with their respective WT controls. N = 11 WT-M, 11 cKO/KO-M, 14 WT-F, 10–11 cKO/KO-F. *p&lt;0.05.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Figure 7 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig7-v2.tif"/></fig></sec><sec id="s2-7"><title>AKT expression under normal and deficiency conditions are regulated similarly between sexes</title><p>Our data support the idea that AKT isoforms play differential roles in behavior, and importantly, these requirements are expressed in a sex-specific fashion. Behavioral results are summarized in <xref ref-type="table" rid="table1">Table 1</xref>. To determine if the basis for these sex differences were due to inherent variation between sexes or a sex-specific compensatory response to <italic>Akt</italic> isoform removal, we conducted biochemical analyses of AKT isoform expression between the sexes. To do this, we immunoblotted proteins from the brains of <italic>Akt</italic> isoform mutant mice and WT controls and measured AKT isoform and activation levels. Comparing WT males and females, we identified higher AKT2 levels in the hippocampus of female mice (<xref ref-type="fig" rid="fig8">Figure 8A</xref>; t(19)=3.045; p=0.007). No sex differences in protein levels were detected for the other isoforms or for total AKT levels measured with a pan-AKT antibody that recognizes all AKT isoforms (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). When AKT activation was measured between the sexes using isoform-specific and pan-AKT serine 473 phosphorylation (pAKT) antibodies, we also found no differences in AKT1, AKT2, and total AKT activation levels (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). These data suggest sex differences in brain expression levels of AKT2 but not the fraction of phosphorylated AKT2 while the other isoforms show similar expression and activation between sexes.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Summary of behavioral impacts of <italic>Akt</italic> isoform deficiency.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="bottom">Behavioral assay</th><th align="center" colspan="6" valign="top">Genotype and/or viral expression manipulation</th></tr><tr><th align="center" valign="top"><italic>Akt1</italic> KO</th><th align="center" valign="top"><italic>Akt2</italic> KO</th><th align="center" valign="top"><italic>Akt3</italic> KO</th><th align="center" valign="top"><italic>Akt1</italic> KO + virally expressed PFC AKT1 (male only)</th><th align="center" valign="top"><italic>Akt1</italic> cKO <break/>(male only)</th><th align="center" valign="top"><italic>Akt1</italic> cKO <italic>Akt3</italic> KO</th></tr></thead><tbody><tr><td valign="top"><bold>OFA</bold></td><td align="center" valign="top">reduced center time in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td></tr><tr><td valign="top"><bold>EPM</bold></td><td align="center" valign="top">reduced open arm time in <bold>males</bold></td><td align="center" valign="top">reduced open arm time in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td></tr><tr><td valign="top"><bold>MWM</bold></td><td align="center" valign="top">reduced platform crossings during probe test in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td><td align="center" valign="top">no effect</td><td align="center" valign="top">reduced quadrant time and platform crossings during probe test in <bold>males</bold> and <bold>females</bold></td></tr><tr><td valign="top"><bold>Contextual fear LTM</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">impaired in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">impaired</td><td align="center" valign="top">impaired in <bold>males</bold> and <bold>females</bold></td></tr><tr><td valign="top"><bold>Cued fear LTM</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">impaired in <bold>males</bold> and <bold>females</bold></td></tr><tr><td valign="top"><bold>Fear extinction learning</bold></td><td align="center" valign="top">enhanced</td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">restored to WT levels</td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td></tr><tr><td valign="top"><bold>Fear extinction LTM</bold></td><td align="center" valign="top">reduced in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no effect</td><td align="center" valign="top">restored to WT levels</td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td></tr><tr><td valign="top"><bold>Fear extinction renewal</bold></td><td align="center" valign="top">reduced in <bold>males</bold></td><td align="center" valign="top">enhanced in <bold>males</bold></td><td align="center" valign="top">no effect</td><td align="center" valign="top">no statistical difference from WT</td><td align="center" valign="top">no effect</td><td align="center" valign="top">n/a</td></tr></tbody></table></table-wrap><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>AKT expression under normal and deficiency conditions are regulated similarly between sexes.</title><p>(<bold>A</bold>) Western blot analysis of AKT isoforms individually, detected with isoform-specific AKT antibodies, and all together, detected with pan-AKT antibodies, in the hippocampus of male versus female WT mice. <italic>Left</italic>: Representative blots. <italic>Middle:</italic> Total levels of each AKT isoform and pan-AKT normalized by GAPDH levels and shown as percent of immunoreactivity in WT males. <italic>Right</italic>: Phosphorylated (p) levels of individual and all (pan) AKT isoforms normalized by their respective total levels and shown as percent of immunoreactivity in WT males. No differences between the sexes were detected except higher AKT2 levels in female WT mice compared with males. N = AKT1,2, pan-AKT: 10 WT-M, 11 WT-F; AKT3: 9 WT-M, 10 WT-F. (<bold>B–C</bold>) Western blot analysis of total (pan-AKT) and phosphorylated (pan-pAKT) AKT levels in the hippocampus of (<bold>B</bold>) male and (<bold>C</bold>) female mice with single-isoform deletions of <italic>Akt1, Akt2,</italic> or <italic>Akt3</italic> compared with their respective WT controls. <italic>Top</italic>: Representative blots. <italic>Left</italic>: Total AKT levels normalized by GAPDH levels and shown as percent of immunoreactivity in WT controls. <italic>Right</italic>: Pan-pAKT levels normalized by pan-AKT levels and shown as percent of immunoreactivity in WT controls. Both sexes showed reduced total AKT levels with single <italic>Akt</italic> isoform deletions and an upregulation of pAKT levels with <italic>Akt1</italic> deficiency. N <italic>= Akt1</italic>: 7 WT-M, 7 KO-M, 8 WT-F, 8 KO-F; <italic>Akt2</italic>: 7 WT-M, 7 KO-M, 6 WT-F, 6 KO-F; <italic>Akt3</italic>: 5 WT-M, 5 KO-M, 4 WT-F, 5 KO-F. (<bold>D</bold>) Western blot analysis of pAKT2 levels normalized by total AKT2 levels in the hippocampus of <italic>Akt1</italic> KO male (<italic>left graph</italic>) and female (<italic>right graph</italic>) mice compared with their respective WT controls and shown as percent of immunoreactivity in WT controls. <italic>Left</italic>: Representative blots. Both sexes showed increased pAKT2 levels in response to <italic>Akt1</italic> deficiency. N = 7 WT-M, 7 KO-M, 8 WT-F, 8 KO-F. (<bold>E</bold>) Western blot analysis of pAKT1 levels normalized by total AKT1 levels in the hippocampus of <italic>Akt3</italic> KO male (<italic>left graph</italic>) and female (<italic>right graph</italic>) mice compared with their respective WT controls and shown as percent of immunoreactivity in WT controls. <italic>Left</italic>: Representative blots. Both sexes showed increased pAKT1 levels in response to <italic>Akt3</italic> deficiency. N = 5 WT-M, 5 KO-M, 8 WT-F, 9 KO-F. *p&lt;0.05.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Figure 8 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig8-v2.tif"/></fig><p>We next measured AKT expression and activation in <italic>Akt</italic> isoform mutants. Using the pan-AKT antibody, we found reduced total AKT levels in all male <italic>Akt</italic> isoform-specific mutants compared with WT controls (<xref ref-type="fig" rid="fig8">Figure 8B</xref>; <italic>Akt1</italic> KO t(12)=3.427, p=0.005; <italic>Akt2</italic> KO t(12)=2.282, p=0.042; <italic>Akt3</italic> KO t(8)=11.79; p&lt;0.0001), with the greatest reduction in <italic>Akt3</italic> KO mice. Interestingly, when we examined AKT activation with the pan-pAKT antibody, we found increased pAKT levels in male <italic>Akt1</italic> KO mice compared with WT controls (<xref ref-type="fig" rid="fig8">Figure 8B</xref>; t(12)=2.541, p=0.026) but no differences in <italic>Akt2</italic> KO or <italic>Akt3</italic> KO males (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). When we performed the same analyses in female <italic>Akt</italic> isoform-specific mutants and WT controls, we observed decreased total AKT levels in a pattern like that found in males (<xref ref-type="fig" rid="fig8">Figure 8C</xref>; <italic>Akt1</italic> KO t(14)=3.507, p=0.004; <italic>Akt2</italic> KO t(10)=2.253, p=0.048; <italic>Akt3</italic> KO t(7)=11.77, p&lt;0.0001). Similarly, we found increased pan-pAKT levels in female <italic>Akt1</italic> KO mice compared with WT controls (<xref ref-type="fig" rid="fig8">Figure 8C</xref>; t(14)=3.456, p=0.004) and no differences in <italic>Akt2</italic> KO or <italic>Akt3</italic> KO females (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). These data provide evidence for similar levels of total AKT isoform expression and activation between sexes in response to removing one <italic>Akt</italic> isoform.</p><p>We next sought to determine how AKT isoforms were individually regulated in the <italic>Akt</italic> mutants. Using the isoform-specific pAKT antibodies to assay AKT isoform activation, we found increased pAKT2 levels in both male and female <italic>Akt1</italic> KO mice compared with WT controls (<xref ref-type="fig" rid="fig8">Figure 8D</xref>; males t(12)=2.645, p=0.021; females t(14)=2.160, p=0.049), contributing to the higher pan-pAKT levels observed in <italic>Akt1</italic> KO mice (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>). In <italic>Akt2</italic> KO mice, we found no difference in pAKT1 levels in either males or females (data not shown), but pAKT1 levels were significantly higher in both male and female <italic>Akt3</italic> KO mice compared with WT controls (<xref ref-type="fig" rid="fig8">Figure 8E</xref>; males t(8)=3.130, p=0.014; females t(15)=3.724, p=0.002). Because <italic>Akt3</italic> KO and WT mice showed similar pan-pAKT levels (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>), the increased pAKT1 levels may compensate for the absence of pAKT3 in <italic>Akt3</italic> KO mice. However, isoform-specific antibodies for AKT3 phosphorylation are not available, so we did not assess pAKT3 levels. These data demonstrate that male and female mice respond similarly to <italic>Akt</italic> isoform deficiency by activating the other AKT isoforms.</p></sec><sec id="s2-8"><title>Single <italic>Akt</italic> isoform deficiency results in minimal changes to some downstream and related AKT signaling pathways</title><p>To investigate the molecular mechanisms underlying the behavioral effects of <italic>Akt</italic> isoform deficiency that we observed, we performed a candidate pathway analysis of AKT signaling in the brain (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>). AKT is known to be regulated upstream by protein 3-phosphoinositide-dependent protein kinase 1 (PDK1), a direct target of several neuronal surface signaling complexes (<xref ref-type="bibr" rid="bib44">Hoeffer and Klann, 2010</xref>). PDK1 activity is regulated by phosphorylation of serine 241 (<xref ref-type="bibr" rid="bib86">Scheid et al., 2005</xref>). A critical downstream substrate of AKT believed to play a role in neuropsychiatric disorders and be a target of psychotropic drugs used to treat the disorders is glycogen synthase kinase three beta (GSK3β) (<xref ref-type="bibr" rid="bib10">Beaulieu et al., 2004</xref>; <xref ref-type="bibr" rid="bib12">Beaulieu et al., 2009</xref>). AKT phosphorylates GSK3β at serine 9, downregulating its activity (<xref ref-type="bibr" rid="bib24">Cross et al., 1994</xref>; <xref ref-type="bibr" rid="bib25">Cross et al., 1995</xref>). The extracellular regulated kinase (ERK) pathway also has been implicated in neurological disorders and neural processes like extinction (<xref ref-type="bibr" rid="bib81">Radulovic and Tronson, 2010</xref>; <xref ref-type="bibr" rid="bib95">Vithayathil et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Albert-Gascó et al., 2020</xref>) and is a parallel signaling pathway to AKT that can have crosstalk (<xref ref-type="bibr" rid="bib103">York et al., 2000</xref>; <xref ref-type="bibr" rid="bib77">Perkinton et al., 2002</xref>; <xref ref-type="bibr" rid="bib91">Sutton and Chandler, 2002</xref>; <xref ref-type="bibr" rid="bib51">Jones et al., 2003</xref>). ERK activity is regulated by phosphorylation of threonine 202/tyrosine 204 (ERK1) and threonine 185/tyrosine 187 (ERK2), which could be indirectly affected by AKT activity (<xref ref-type="bibr" rid="bib4">Ahn et al., 1990</xref>; <xref ref-type="bibr" rid="bib75">Payne et al., 1991</xref>).</p><p>Using western blotting, we examined brain tissue from <italic>Akt</italic> isoform mutant mice to determine if PDK1, GSK3β, and ERK1/2 signaling were affected in an isoform- or sex-specific fashion. Comparing <italic>Akt1</italic> KO and WT samples, we found no significant differences in phosphorylated or total levels of the proteins examined from the hippocampus for either sex (<xref ref-type="fig" rid="fig9">Figure 9A,B</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Because AKT1 loss affected extinction (<xref ref-type="fig" rid="fig4">Figure 4</xref>), we also examined signaling in the PFC of <italic>Akt1</italic> KO mice but found no differences in males (<xref ref-type="fig" rid="fig9">Figure 9C</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). <italic>Akt1</italic> KO females, however, showed reduced pGSK3β levels in the PFC compared with WT controls (<xref ref-type="fig" rid="fig9">Figure 9D</xref>; t(12)=3.567; p=0.004). Comparing <italic>Akt2</italic> KO and WT hippocampal samples, we found no significant differences in the proteins examined for either sex (<xref ref-type="fig" rid="fig9">Figure 9E,F</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In the hippocampus of <italic>Akt3</italic> KO mice, we previously found reduced pGSK3β levels in males compared with WT controls (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). In females, we found no difference in pGSK3β levels between <italic>Akt3</italic> KO and WT hippocampal samples (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref>). We also examined if interneuronal expression was different between the sexes. Because we posit that interneuronal AKT1 activity in the PFC is required for extinction learning in males based on our results (<xref ref-type="fig" rid="fig4">Figures 4</xref>–<xref ref-type="fig" rid="fig6">6</xref>), any sex difference in interneuronal expression in the PFC could contribute to the observed results. Using the interneuronal markers parvalbumin (PV) and glutamate decarboxylase 67 (GAD67), we assessed the number of PV-positive interneurons and the level of GAD67 in the WT mouse PFC from both sexes and found no differences between males and females (<xref ref-type="fig" rid="fig9s3">Figure 9—figure supplement 3</xref>). While certainly not a comprehensive examination of <italic>Akt</italic> isoform deficiency impacts on signaling in the brain, these results may help to explain the isoform- and sex-specific behavioral effects we observed in <italic>Akt</italic> mutant mice and suggest additional pathways are involved.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Examination of <italic>Akt</italic> isoform deficiency effects on neuromolecular signaling pathways.</title><p>Upstream signaling of AKT was assessed by measuring phosphorylation levels of phosphoinositide-dependent protein kinase 1 (PDK1) at serine 241. Downstream signaling of AKT was assessed by measuring phosphorylation levels of glycogen synthase kinase three beta (GSK3β) at serine 9. Crosstalk between AKT and the extracellular regulated kinase (ERK) pathway was assessed by measuring ERK1 and ERK2 phosphorylation levels at threonine 204/tyrosine 202 and threonine 185/tyrosine 187, respectively. See <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref> for schematic of pathways. (<bold>A</bold>) Western blot analysis of phosphorylated (p) proteins normalized by their respective total levels in the hippocampus (HPC) of <italic>Akt1</italic> KO males and shown as percent of immunoreactivity in WT controls. <italic>Left</italic>: Representative blots. N = 7 WT, 7 KO. (<bold>B</bold>) Western blot analysis of signaling in the HPC of <italic>Akt1</italic> KO females. N = 7 WT, 7 KO. (<bold>C</bold>) Western blot analysis of signaling in the prefrontal cortex (PFC) of <italic>Akt1</italic> KO males. pPDK1, pERK1/2: N = 6 WT, 6 KO; pGSK3β N = 8 WT, 8 KO. (<bold>D</bold>) Western blot analysis of signaling in the PFC of <italic>Akt1</italic> KO females showed reduced pGSK3β levels compared with WT controls. pPDK1, pERK1/2: N = 6 WT, 6 KO; pGSK3β N = 7 WT, 7 KO. (<bold>E</bold>) Western blot analyses of signaling in the HPC of <italic>Akt2</italic> KO males and (<bold>F</bold>) females compared to their respective WT controls. N = 5 WT-M, 5 KO-M, 5 WT-F, 5 KO-F. *p&lt;0.05.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Figure 9 source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56630-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Schematic of AKT-dependent and interacting signaling pathways.</title><p>Candidate pathways (boxed) upstream (PDK1), downstream (GSK3β), and parallel (ERK) to AKT were examined by western blot analysis to assess the impact of <italic>Akt</italic> isoform deficiency on signaling in the brain.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title><italic>Akt3</italic> deficiency does not alter GSK3β activation in the hippocampus of female mice.</title><p>Western blot analysis of GSK3β phosphorylation at serine 9 (pGSK3β) normalized by total GSK3β levels reveals no difference in the hippocampus between female <italic>Akt3</italic> KO and WT mice. GAPDH, loading control. N = 5/group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig9-figsupp2-v2.tif"/></fig><fig id="fig9s3" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 3.</label><caption><title>Interneuron expression in the PFC of male and female WT mice.</title><p>(<bold>A</bold>) Representative immunostaining for the interneuronal markers parvalbumin (PV, red) and glutamate decarboxylase 67 (GAD67, green) in the prelimbic region of the PFC of male and female WT mice. Yellow arrows, interneuronal cell bodies co-expressing PV and GAD67. Hoechst (blue), nuclear stain. Scale bars, 200 µm. (<bold>B</bold>) Quantification of the average number of PV-positive cells in the PFC corresponding to the white box in (<bold>A</bold>) shows no difference between male and female WT mice. N = 3 mice/sex. Cell counts were averaged from five coronal sections of the PFC between 1.98 and 1.70 mm AP in one hemisphere for each mouse and from two observers blind to the experimental groups. (<bold>C</bold>) Western blot analysis of PFC lysates from WT mice shows no significant difference in GAD67 levels between sexes. β-actin, loading control N = 6/sex.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56630-fig9-figsupp3-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We provide evidence for <italic>Akt</italic> isoform-specific functions underlying cognitive processes for affective behavior, spatial and contextual memory formation, and extinction learning and memory. Our study is the first to comprehensively investigate the behavioral consequences of <italic>Akt</italic> deficiency in the context of sex-specific effects, brain-specific <italic>Akt1</italic> deletion, and simultaneous <italic>Akt1</italic> and <italic>Akt3</italic> removal from the brain. We find that AKT1 loss more broadly affects neural function, impacting anxiety-related behavior, spatial memory, extinction learning, and renewal in <italic>Akt1</italic> KO mice but only the males. This may identify a role for <italic>Akt1</italic> outside the brain or during development that preferentially affects males. We also demonstrate that <italic>Akt2</italic> is required for the display of normal anxiety-like behavior and contextual fear memory. Although we found no evidence for <italic>Akt3</italic>-specific roles in the assays we performed, <italic>Akt3</italic> removal did enhance phenotypes in the <italic>Akt1</italic> mutant background, importantly extending them to females. All behavior results are summarized in <xref ref-type="table" rid="table1">Table 1</xref>. Finally, we found that the loss of individual AKT isoforms in the brain resulted in increased activation of the other isoforms and minimal changes to upstream PDK1, downstream GSK3β, and crosstalk with ERK signaling, with some sex-specific differences in AKT regulation and signaling pathways. Sex differences in neuropsychiatric disorders are well-recognized but poorly understood and understudied. By identifying sex-specific effects on AKT isoform-specific and redundant activity in cognitive processes, our study provides valuable new insight into how the highly influential AKT signaling pathway may affect diagnosis and treatment of neuropsychiatric disorders.</p><sec id="s3-1"><title>AKT isoforms and behaviors linked to psychiatric disorders</title><p>Examining affective behavior, spatial and contextual memory, and extinction in mice has translational relevance to neuropsychiatric disorders. Anxiety is featured in many psychiatric conditions, including MDD, bipolar disorder (BD), and schizophrenia (<xref ref-type="bibr" rid="bib8">American Psychiatric Association, 2013</xref>). Hippocampus-dependent memory functions such as spatial and episodic memory are impaired in schizophrenia (<xref ref-type="bibr" rid="bib2">Achim and Lepage, 2003</xref>; <xref ref-type="bibr" rid="bib93">Titone et al., 2004</xref>; <xref ref-type="bibr" rid="bib3">Achim and Lepage, 2005</xref>; <xref ref-type="bibr" rid="bib82">Ragland et al., 2015</xref>). Defects in extinction processes are observed in anxiety, depression, and schizophrenia (<xref ref-type="bibr" rid="bib31">Elliott et al., 1997</xref>; <xref ref-type="bibr" rid="bib15">Boks et al., 2000</xref>; <xref ref-type="bibr" rid="bib68">Maren and Holmes, 2016</xref>; <xref ref-type="bibr" rid="bib22">Craske et al., 2018</xref>). Extinction is also used in cognitive behavioral therapy to treat fear-associated disorders like PTSD and panic disorders (<xref ref-type="bibr" rid="bib78">Powers et al., 2017</xref>). Therefore, delineating AKT isoform-relevant information about the neural circuitry and molecular signaling underlying these processes modeled in mice may aid therapeutic strategies.</p><p>Our study is the first to report on the effects of <italic>Akt</italic> deficiency in several murine behaviors and expands previous knowledge on the contribution of AKT isoforms. For affective behaviors, no prior study had examined <italic>Akt1</italic> KO mice. An earlier study reported higher anxiogenic-like behaviors in <italic>Akt2</italic> KO mice, as we report, but did not examine sex-specific effects (<xref ref-type="bibr" rid="bib59">Leibrock et al., 2013</xref>). In <italic>Akt3</italic> KO mice, one earlier study reported increased anxiogenic-like EPM behavior (<xref ref-type="bibr" rid="bib13">Bergeron et al., 2017</xref>) while another reported hyperactivity but no anxiety-like behavioral alterations (<xref ref-type="bibr" rid="bib45">Howell et al., 2017</xref>). The discrepancies may result from using smaller sample sizes than our study, which can cause cohort effects, and mixing sexes. For spatial memory, previous studies had tested <italic>Akt1</italic> KO mice in the MWM but did not examine sex-based performance comprehensively and reported conflicting results (<xref ref-type="bibr" rid="bib9">Balu et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Chang et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Wang et al., 2017</xref>). While our results support <xref ref-type="bibr" rid="bib9">Balu et al., 2012</xref>, reasons for discrepancies with the other studies are unclear, but in <xref ref-type="bibr" rid="bib19">Chang et al., 2016</xref> the unusually superior MWM performance of WT females, achieving maximal training performance after just one day, makes the apparently impaired KO performance difficult to interpret. Only one prior study examined MWM performance in <italic>Akt2</italic> KO mice and found no effects (<xref ref-type="bibr" rid="bib59">Leibrock et al., 2013</xref>), confirmed by our results for both sexes. In <italic>Akt3</italic> KO mice, previous MWM studies had been conducted with two reporting similar findings to ours (<xref ref-type="bibr" rid="bib13">Bergeron et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Howell et al., 2017</xref>) and another reporting a mild learning impairment but normal memory (<xref ref-type="bibr" rid="bib96">Wang et al., 2017</xref>). For associative fear conditioning, unlike our results, a previous study reported impaired contextual fear memory in <italic>Akt1</italic> mutants (<xref ref-type="bibr" rid="bib9">Balu et al., 2012</xref>) but used far fewer mice than our study and did not consider sex-specific effects. Fear extinction in <italic>Akt1</italic> mutants and both fear conditioning and extinction in <italic>Akt2</italic> mutants had not been studied previously. A prior study examined fear extinction in <italic>Akt3</italic> KO mice using a different protocol but found no effects (<xref ref-type="bibr" rid="bib45">Howell et al., 2017</xref>), in agreement with our findings. Finally, no prior study had examined the behavioral impacts of conditional AKT1 deficiency or loss of two isoforms simultaneously. Our results suggest that AKT1 and AKT3 have overlapping functions but exert their effects in a sex-specific fashion, perhaps pointing to compensatory activities present in females but not males, whereas AKT2 has unique but also sex-specific functions.</p><p>These results are important given our previous work and others showing differential AKT isoform expression in the brain (<xref ref-type="bibr" rid="bib104">Zeisel et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">DuBois et al., 2019</xref>). AKT1 and AKT3 are expressed in overlapping neuronal populations but only AKT1 is found in interneurons (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>) while only AKT3 is found in oligodendrocytes (<xref ref-type="bibr" rid="bib28">DuBois et al., 2019</xref>). This may explain the synergistic effects of <italic>Akt1</italic> and <italic>Akt3</italic> removal on memory and why <italic>Akt1</italic> removal alone was sufficient to affect anxiety-like behavior and fear extinction: GABAergic mechanisms linked to interneuronal function were shown previously to mediate these behaviors (<xref ref-type="bibr" rid="bib27">Delamater et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Maren et al., 2013</xref>). Indeed, our rescue experiment with viral-mediated AKT1 restoration in the PL and IL regions of the PFC of <italic>Akt1</italic> KO mice highlight a critical role for AKT1 in these brain regions for extinction processes (<xref ref-type="fig" rid="fig5">Figure 5</xref>). This experiment contrasts with the results of our conditional <italic>Akt1</italic> KO studies, where <italic>Akt1</italic> removal from excitatory neurons of the forebrain (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) did not affect extinction (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Our AKT1 restoration experiment does not distinguish between AKT1 activity in excitatory and inhibitory neurons for rescuing extinction phenotypes in <italic>Akt1</italic> KO mice (<xref ref-type="fig" rid="fig4">Figure 4</xref>); therefore, the results of our conditional <italic>Akt1</italic> removal data suggest that AKT1 activity within interneurons is required for normal extinction learning. Future efforts aimed at refining AKT1 activity using interneuronal restoration of AKT1 expression or interneuron-specific <italic>Akt1</italic> removal may help to resolve this question. Another implication of our viral rescue result taken together with our conditional <italic>Akt1</italic> removal experiments is that AKT1 activity is unlikely to be required during perinatal development to affect cognition and memory (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>); AKT1 activity appears to be required during active neurobiological processes rather than developmentally. AKT3 may be able to compensate for AKT1 during development but not post-developmentally in active neurobiological processes like cognition and synaptic plasticity (<xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). The behavioral effects of <italic>Akt2</italic> deficiency are also interesting because AKT2 is not expressed in neurons but rather astrocytes of the mouse brain (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>), and little has been known about astrocyte function in cognitive processes. Because initial learning is normal in the assays we performed (<xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig6">6</xref>), sensory processing is likely intact in the <italic>Akt</italic> mutants we studied, but our experiments do not distinguish between consolidation or retrieval processes. Future experiments using reversible temporal control of AKT activity may be used to address these questions.</p></sec><sec id="s3-2"><title>Human and animal studies linking AKT to psychiatric disorders</title><p>Abnormal AKT signaling has emerged as a potential mechanism underlying several psychiatric disorders. Schizophrenia, for example, has been associated with SNPs in <italic>AKT1</italic> (<xref ref-type="bibr" rid="bib48">Ikeda et al., 2004</xref>; <xref ref-type="bibr" rid="bib92">Tan et al., 2008</xref>; <xref ref-type="bibr" rid="bib14">Blasi et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Karege et al., 2012</xref>) and <italic>AKT3</italic> (<xref ref-type="bibr" rid="bib79">Psychosis Endophenotypes International Consortium et al., 2014</xref>), reduced AKT1 levels in patient brains (<xref ref-type="bibr" rid="bib33">Emamian et al., 2004</xref>), and pathogenic AKT signaling (<xref ref-type="bibr" rid="bib64">Liu et al., 2013</xref>). Other studies have failed to find statistically robust links between schizophrenia candidate genes like <italic>AKT</italic> and the disorder (<xref ref-type="bibr" rid="bib65">Loh et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Purcell et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Farrell et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Johnson et al., 2017</xref>). However, phenotypic and genetic heterogeneity associated with complex brain disorders like schizophrenia, combined with divergent clinical diagnoses, may impede current genomic studies from capturing AKT contributions. Additionally, post-translational modification of AKT is critical for its activity and highly heritable (<xref ref-type="bibr" rid="bib47">Hutz et al., 2011</xref>) yet seldom considered in genetic association studies. Functional studies provide strong evidence for AKT involvement in schizophrenia. Magnetic resonance imaging studies have linked AKT signaling and SNPs in the pathway to structural and functional brain abnormalities in schizophrenia patients (<xref ref-type="bibr" rid="bib49">Jagannathan et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Nicodemus et al., 2010</xref>; <xref ref-type="bibr" rid="bib99">Wolthusen et al., 2015</xref>). Antipsychotics for treating schizophrenia, which antagonize dopamine receptor-2 function, activate AKT and inhibit its substrate GSK3 (<xref ref-type="bibr" rid="bib33">Emamian et al., 2004</xref>; <xref ref-type="bibr" rid="bib7">Alimohamad et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Li et al., 2007</xref>; <xref ref-type="bibr" rid="bib12">Beaulieu et al., 2009</xref>). Furthermore, genetic and pharmacological manipulations of the AKT/GSK3 pathway affect dopaminergic signaling and schizophrenia-related behaviors (<xref ref-type="bibr" rid="bib10">Beaulieu et al., 2004</xref>; <xref ref-type="bibr" rid="bib33">Emamian et al., 2004</xref>; <xref ref-type="bibr" rid="bib39">Gould et al., 2007</xref>). Atypical antipsychotics also promote AKT activity (<xref ref-type="bibr" rid="bib7">Alimohamad et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Li et al., 2007</xref>). In other disorders, AKT has been implicated by post-mortem brain tissue from suicide victims showing decreased AKT activity (<xref ref-type="bibr" rid="bib46">Hsiung et al., 2003</xref>), genetic studies associating <italic>AKT1</italic> SNPs with BD (<xref ref-type="bibr" rid="bib53">Karege et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Karege et al., 2012</xref>) and depression (<xref ref-type="bibr" rid="bib32">Ellsworth et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Pereira et al., 2014</xref>), and pharmacological studies showing that lithium, used widely to treat schizophrenia and BP (<xref ref-type="bibr" rid="bib18">Chalecka-Franaszek and Chuang, 1999</xref>; <xref ref-type="bibr" rid="bib26">De Sarno et al., 2002</xref>; <xref ref-type="bibr" rid="bib10">Beaulieu et al., 2004</xref>; <xref ref-type="bibr" rid="bib11">Beaulieu et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Nciri et al., 2013</xref>), and the antidepressant ketamine (<xref ref-type="bibr" rid="bib74">Park et al., 2014</xref>) induce AKT signaling. Altogether, these studies suggest AKT is a key factor in the manifestation of psychiatric disorders and a key mechanism of action by current treatments. Because these disorders are heterogeneous and available therapies still have limited effectiveness, our data identifying specific and redundant roles for AKT isoforms, combined with the cell-specific expression of AKT in the brain (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">DuBois et al., 2019</xref>), will be useful for subdividing these disorders to improve diagnostic measures and develop more targeted treatments.</p></sec><sec id="s3-3"><title>Sex-specific effects of AKT signaling?</title><p>Sex-dependent differences in mental health are well-documented. Women are disproportionately impacted by affective disorders (<xref ref-type="bibr" rid="bib84">Rubinow and Schmidt, 2019</xref>), with higher rates of MDD (<xref ref-type="bibr" rid="bib56">Kessler et al., 1993</xref>; <xref ref-type="bibr" rid="bib97">Weissman et al., 1993</xref>; <xref ref-type="bibr" rid="bib57">Kessler et al., 2005</xref>) and anxiety disorders (<xref ref-type="bibr" rid="bib102">Yonkers et al., 2003</xref>; <xref ref-type="bibr" rid="bib66">Maeng and Milad, 2015</xref>). In men, schizophrenia is more prevalent (<xref ref-type="bibr" rid="bib1">Abel et al., 2010</xref>) but over the course of normal aging, schizophrenia impacts women at higher rates (<xref ref-type="bibr" rid="bib41">Häfner, 2003</xref>; <xref ref-type="bibr" rid="bib69">Meesters et al., 2012</xref>). Sex-dependent effects also are evident in treatment profiles for neuropsychiatric disorders. Studies have found that women are more responsive to available treatments for schizophrenia and BD (<xref ref-type="bibr" rid="bib89">Seeman, 2012</xref>; <xref ref-type="bibr" rid="bib23">Crawford and DeLisi, 2016</xref>; <xref ref-type="bibr" rid="bib5">Alberich et al., 2019</xref>). In MDD, women generally report better treatment effects but also worse outcomes during tricyclic treatment (<xref ref-type="bibr" rid="bib55">Keers and Aitchison, 2010</xref>). In female mice, ketamine exerts more potent and rapid effects in the forced swim test compared with males (<xref ref-type="bibr" rid="bib36">Franceschelli et al., 2015</xref>). Only one prior study has examined sex-dependent effects of AKT signaling in a neurological context, showing <italic>Akt1</italic> KO female but not male mice were resistant to pentylenetetrazol-induced epileptic effects compared with controls (<xref ref-type="bibr" rid="bib19">Chang et al., 2016</xref>), which is consistent with the generally increased susceptibility of <italic>Akt1</italic> KO males to behavioral alterations in the present study. Sex-specific differences in <italic>Akt</italic> mutant behavior reported here and previously cannot be explained by AKT expression or activation differences between the sexes. Our data show that with the exception of AKT2 total levels, male and female mice exhibit similar AKT isoform levels (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), activation under <italic>Akt</italic> deficiency conditions (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>), and compensatory responses to AKT isoform loss (<xref ref-type="fig" rid="fig8">Figure 8D,E</xref>). Because AKT levels and activation are largely similar between males and females, sex-related differences in behavior are likely defined by sex-related differences in AKT signaling and interacting pathways. To begin to address this idea, we examined candidate signaling upstream, downstream, and parallel of AKT (<xref ref-type="fig" rid="fig9">Figure 9</xref> and <xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). Interestingly, we found reduced phosphorylation of the AKT substrate GSK3β in the PFC of <italic>Akt1</italic> KO females. Why this was not observed in males is of significant future interest. It may indicate that for some downstream AKT targets, such as GSK3β, males may recruit additional signaling to modulate their activities. These additional or compensatory pathways that normalize GSK3β signaling in males may contribute to the behavioral differences observed between male and female <italic>Akt1</italic> mutant mice (<xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig4">4</xref>). By contrast, pGSK3β levels were reduced in the hippocampus of <italic>Akt3</italic> KO male mice but unchanged in females compared with WT controls (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref> and <xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). This may indicate that AKT substrates also are regulated in <italic>Akt</italic> isoform-specific pools, each with specialized regulation. These findings while very preliminary, do indicate that sex-specific differences in AKT-dependent or -interacting signaling pathways exist. Future investigation using more comprehensive and unbiased methodologies like RNAseq or protein mass spectrometry should help identify these sex-specific signaling differences. Our findings greatly extend understanding of sex-specific AKT isoform effects in cognitive processes, which further supports the need for more specialized diagnoses and treatments. Future studies will be important to determine how AKT is differentially expressed and regulated in the brain between males and females.</p></sec><sec id="s3-4"><title>Conclusion</title><p>Neuropsychiatric disorders are major health and economic concerns, with many afflicted individuals going undiagnosed or misdiagnosed and inadequately treated. Given the links between AKT and neuropsychiatric disorders, more studies like ours are needed to increase understanding of how this potent molecular pathway, with multiple isoforms, impacts behaviors and neurobiological processes modeled for these disorders. Because treatment responses can differ based on sex, newer more effective treatments may be developed if sex-dependent differences in critical neuropsychiatric signaling pathways, such as AKT, are better understood.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">anti-AKT1 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 2938; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_915788">AB_915788</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT1 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 75692; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2716309">AB_2716309</ext-link></td><td valign="top">IHC (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT1 phospho-S473 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9081; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11178946">AB_11178946</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT2 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 2964; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331162">AB_331162</ext-link></td><td valign="top">WB (1:1000); IHC (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT2 phospho-S474 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 8599; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2630347">AB_2630347</ext-link></td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT3 (Mouse monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 8018; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10859371">AB_10859371</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-AKT3 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 14982; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2716311">AB_2716311</ext-link></td><td valign="top">IHC (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-pan-AKT (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 4685; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2225340">AB_2225340</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-pan-AKT phospho-S473 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 4058; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331168">AB_331168</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-GAPDH (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 5174; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10622025">AB_10622025</ext-link></td><td valign="top">WB (1:20000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-β-actin (Mouse monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 3700; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2242334">AB_2242334</ext-link></td><td valign="top">WB (1:20000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-PDK1 phospho-S241 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 3061; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2161919">AB_2161919</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-PDK1 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 3062; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2236832">AB_2236832</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-GSK3β phospho-S9 (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 5558; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10013750">AB_10013750</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-GSK3β (Rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9315; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_490890">AB_490890</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-ERK1/2 phospho-T202/Y204 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9101; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331646">AB_331646</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-ERK1/2 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9102; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330744">AB_330744</ext-link></td><td valign="top">WB (1:7500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-NeuN (Mouse monoclonal)</td><td valign="top">Novus</td><td valign="top">Cat# NBP1-92693; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11036146">AB_11036146</ext-link></td><td valign="top">IHC (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-GAD67 (Mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">Cat# MAB5406 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2278725">AB_2278725</ext-link></td><td valign="top">IHC (1:1500) <break/>WB (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-paravalbumin (Mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">Cat# MAB1572; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2174013">AB_2174013</ext-link></td><td valign="top">IHC (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-rabbit Cy3 (Donkey polyclonal)</td><td valign="top">Jackson ImmunoResearch</td><td valign="top">Cat# 711-165-152; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2307443">AB_2307443</ext-link></td><td valign="top">(1:250)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-mouse IgG2b Alexa 647 (Goat polyclonal)</td><td valign="top">Invitrogen</td><td valign="top">Cat# A-21242; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2535811">AB_2535811</ext-link></td><td valign="top">(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-mouse IgG1 Alexa 488 (Goat polyclonal)</td><td valign="top">Invitrogen</td><td valign="top">Cat# A-21121; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2535764">AB_2535764</ext-link></td><td valign="top">(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-mouse HRP (Goat polyclonal)</td><td valign="top">Promega</td><td valign="top">Cat# W4021; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_430834">AB_430834</ext-link></td><td valign="top">(1:5000–20000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-rabbit HRP (Goat polyclonal)</td><td valign="top">Promega</td><td valign="top">Cat# W4011; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_430833">AB_430833</ext-link></td><td valign="top">(1:5000–20000)</td></tr><tr><td valign="top">Other</td><td valign="top">Hoechst</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# H3569; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2651133">AB_2651133</ext-link></td><td valign="top">(1:3000)</td></tr><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>), both sexes</td><td valign="top"><italic>Akt1<sup>tm1Mbb</sup></italic>, C57BL/6 (<italic>Akt1</italic> KO)</td><td valign="top">Jackson Laboratory</td><td valign="top">Stock # 004912; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:004912">IMSR_JAX:004912</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>), both sexes</td><td valign="top"><italic>Akt2<sup>tm1.1Mbb</sup></italic>, C57BL/6 (<italic>Akt2</italic> KO)</td><td valign="top">Jackson Laboratory</td><td valign="top">Stock # 006966; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:006966">IMSR_JAX:006966</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>), both sexes</td><td valign="top"><italic>Akt3<sup>tm1.3Mbb</sup></italic>, C57BL/6 (<italic>Akt3</italic> KO)</td><td valign="top"><xref ref-type="bibr" rid="bib30">Easton et al., 2005</xref>; PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549378/">PMC549378</ext-link></td><td valign="top">MGI Cat# 3804003, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:3804003">MGI:3804003</ext-link></td><td valign="top">Obtained from Birnbaum lab (UPenn)</td></tr><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>), both sexes</td><td valign="top"><italic>Akt1<sup>tm2.2Mbb</sup></italic>,C57BL/6 (<italic>Akt1<sup>fl/fl</sup></italic>)</td><td valign="top">Jackson Laboratory</td><td valign="top">Stock #026474; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:026474">IMSR_JAX:026474</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent (<italic>Mus musculus</italic>), females only</td><td valign="top"><italic>Tg<sup>(CamkIIa-Cre)T29Stl</sup>,</italic> C57BL<italic>/6</italic> (<italic>Camk2a</italic>-Cre)</td><td valign="top"><xref ref-type="bibr" rid="bib42">Hoeffer et al., 2008</xref>; PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630531/">PMC2630531</ext-link></td><td valign="top">MGI Cat# 6273652, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:6273652">MGI:6273652</ext-link></td><td valign="top">Obtained from Kelleher lab (MIT) before the Tonegawa lab submitted a strain to Jax with same name; <bold>not</bold> same strain as listed at JAX. Expression properties for this line in <xref ref-type="bibr" rid="bib42">Hoeffer et al., 2008</xref>.</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">hSyn-hAKT1-hSyn-eGFP (AAV)</td><td valign="top">Vector Biolabs</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_011010">SCR_011010</ext-link> AKT1:Genbank RefSeq# BC000479.2</td><td valign="top">Commercially produced custom construct</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">hSyn-eGFP-Cre (AAV)</td><td valign="top">Penn Vector Core</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene">Addgene</ext-link> 105540</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">IBM SPSS Statistics</td><td valign="top">IBM Analytics</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002865">SCR_002865</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism</td><td valign="top">GraphPad</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageQuant TL</td><td valign="top">GE Healthcare</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014246">SCR_014246</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Icy</td><td valign="top">Institut Pasteur and France-BioImaging</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_010587">SCR_010587</ext-link></td><td valign="top">Open source image processing</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>Single-isoform knockout (KO) mice for <italic>Akt1</italic>, <italic>Akt2</italic>, and <italic>Akt3</italic> as well as <italic>Akt1<sup>fl/fl</sup> Akt3 KO</italic> mice were generated on a C57B/l6 background as previously described (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>). To generate mice with conditional removal of <italic>Akt1</italic> in forebrain excitatory neurons, we bred <italic>Akt1<sup>fl/fl</sup></italic> or <italic>Akt1<sup>fl/fl</sup> Akt3</italic> KO mice with <italic>Akt1</italic><sup>fl/+</sup> crossed to <italic>Camk2a::Cre</italic> mice on a C57Bl/6 background (<xref ref-type="bibr" rid="bib42">Hoeffer et al., 2008</xref>). Because it would have been logistically prohibitive to generate all <italic>Akt</italic> mutant combinations from a single progenitor line, <italic>Akt</italic> mutant strains were maintained and tested separately. Mice from all strains were assessed for general health and sensory and locomotor capacities compared to their wild-type (WT) littermates. Apart from previously reported significant size differences in <italic>Akt1</italic> and <italic>Akt3</italic> mutant backgrounds (<xref ref-type="bibr" rid="bib20">Cho et al., 2001</xref>; <xref ref-type="bibr" rid="bib30">Easton et al., 2005</xref>) and lower than expected Mendelian frequencies for <italic>Akt1</italic> KO mice (<xref ref-type="bibr" rid="bib20">Cho et al., 2001</xref>), KO and WT mice were indistinguishable from each other. We also observed no significant differences in mortality during the testing period. Mice were group-housed in the same facility and maintained on a 12:12 hr light:dark schedule with food and water available <italic>ad libitum</italic>. Mice of both sexes were used in all experiments and tested over multiple independent cohorts at 3–6 months old. All procedures were approved by the University of Colorado, Boulder’s Institutional Animal Care and Use Committee and conformed to the National Institutes of Health’s <italic>Guide for the Care and Use of Laboratory Animals</italic>.</p></sec><sec id="s4-2"><title>Behavioral assays</title><p>Timeline: A schematic representation of the experimental timeline is shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. For <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig4">4</xref> and <xref ref-type="fig" rid="fig6">6</xref>, mice were tested first in the OFA, then EPM the next day, followed by either MWM testing over 13 days or associative fear memory and extinction testing over 20 days. For <xref ref-type="fig" rid="fig5">Figure 5</xref>, mice were allowed to recover from surgery for 21 days and handled for three consecutive days, 30 min each day, immediately prior to fear conditioning. For <xref ref-type="fig" rid="fig7">Figure 7</xref>, mice were tested first in the OFA, then EPM the next day, followed by either MWM testing over 13 days or associative fear memory testing. Mice were acclimated to the testing room for 1 hr before each assay. All studies were performed with experimenters blind to genotype.</p><p>OFA: Mice were allowed 10 min to explore a white Plexiglas arena (40 × 40 cm<sup>2</sup>) with 180 lux overhead lighting and 55 dB white noise present for their entire duration in the testing room. Data were collected and analyzed using the Ethovision XT video tracking system (Noldus, Wageningen, Netherlands), with the center zone defined as the area 10 cm from the arena walls.</p><p>EPM: Mice were allowed 5 min to explore a white EPM arena (30 cm arm length) under similar testing conditions to OFA and activity was analyzed with Ethovision XT as previously described (<xref ref-type="bibr" rid="bib43">Hoeffer et al., 2013</xref>).</p><p>MWM: Mice were trained over 8 days as previously described (<xref ref-type="bibr" rid="bib100">Wong et al., 2015</xref>) to locate a hidden escape platform 2–3 cm below the surface of a pool (112 cm diameter) of opaque water using visual cues outside of the pool. After the probe test on day 8, a reversal phase was introduced on days 9–11 in which mice were similarly trained to locate the hidden platform in the opposite quadrant. On days 12–13, mice were tested for visual acuity using a visible escape platform as previously described (<xref ref-type="bibr" rid="bib100">Wong et al., 2015</xref>). Data were collected and analyzed using Ethovision XT.</p><p>Fear conditioning and extinction: Mice were trained on day one with two pairings of a tone (CS, 30 s, 85 dB white noise) and foot-shock (US, 2 s, 0.5-mA) presentation, and freezing behavior was measured to assess fear acquisition. On day 2, contextual and cued long-term memory (LTM) were assessed by re-exposing mice to the training context (white light, grid floor, and peppermint odor) or to the CS in a novel context, respectively, with no US. Order of testing contextual and cued LTM with 1 hr between tests for each mouse was randomly counterbalanced among animals. Memory was measured as percent time spent freezing during the 5 min contextual test or during the two 30 s CS presentations given 1 min apart in the cued test. On day 7, mice received extinction training in the cued LTM testing environment over three consecutive days with a 35 min session each day consisting of 20 (30 s) CS exposures at varying intervals. On day 10, extinction LTM was assessed like cued LTM in a novel context. On day 20, renewal of conditioned fear was performed by re-exposing mice to the CS in the original training context using the same protocol as for training except no US was delivered. Baseline freezing was also monitored prior to the first CS presentation in any session. Context novelty was generated using alternate lighting (red light), walls and flooring (changeable acrylic inserts with different display patterns or textures), and odorants (vanilla or lavender) compared to the training environment.</p></sec><sec id="s4-3"><title>Intra-PFC AAV injections</title><p>Akt1 WT and KO male mice 3–4 months old were anesthetized with isoflurane and stabilized on a stereotaxic apparatus (Kopf Instruments) for bilateral injections of recombinant AAV vectors into the prefrontal cortex (PFC) at Bregma coordinates 1.98 mm anterioposterior, ±0.5 mm mediolateral, and −2.35 mm dorsoventral. <italic>Akt1</italic> KO mice were administered AAV (1 µL at 2.5e12 GC/mL over 10 min) to express either human AKT1-GFP (Vector Biolabs, Malvern, PA) or Cre-GFP (Penn Vector Core, Philadelphia, PA) under the human synapsin I promoter (hSyn) in each hemisphere. WT mice received only AAV-hSyn::Cre-GFP injections. Injectors were removed after an additional 10 min post-AAV infusion. Following standard post-operative care, mice remained in their home cages for 21 d post-surgery to allow AAV expression before fear memory and extinction testing. Following behavior tests, the brains from these mice were fixed and sectioned for microscopy using similar procedures described previously (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>) to confirm AAV expression in the PFC by GFP visualization and AKT1 immunostaining.</p></sec><sec id="s4-4"><title>Western blotting</title><p>Brain tissues were isolated from a subset of mice after completion of behavioral testing (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and blotted using procedures described previously to probe phosphorylated and total levels of AKT isoforms, PDK1, GSK3β, and ERK (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>).</p></sec><sec id="s4-5"><title>Immunohistochemistry</title><p>Fluorescent immunostaining of fixed brain sections from transcardially perfused mice was performed using similar procedures described previously (<xref ref-type="bibr" rid="bib60">Levenga et al., 2017</xref>) to visualize expression of AKT1, AKT3, NeuN, PV, and GAD67.</p></sec><sec id="s4-6"><title>Experimental design and statistical analysis</title><p>All data are presented as the mean ± SEM and were statistically evaluated using SPSS (IBM Corporation). Data were analyzed for each sex by Student’s t-test, one-way analysis of variance (ANOVA) or one-way repeated-measures ANOVA where appropriate, with genotype as the between-subjects factor (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Homogeneity of variance was assessed using Levene’s test. Outliers were excluded based on Grubbs’ method, experimental criteria, or equipment errors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). <italic>Akt</italic> isoform mutants were maintained in separate lines and were not tested together, so <italic>Akt</italic> isoform experimental groups were compared only with their respective WT littermates and not analyzed together. Because male and female mice were tested separately, we also did not combine sexes for statistical analyses. However, we have included two-way ANOVA with sex and genotype as independent variables for each <italic>Akt</italic> mutant line (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) showing that our findings using either statistical approach are largely unchanged. Experiments were designed based on power analyses derived from previously conducted similar experiments (<xref ref-type="bibr" rid="bib42">Hoeffer et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Hoeffer et al., 2013</xref>; <xref ref-type="bibr" rid="bib100">Wong et al., 2015</xref>). All behavior experiments used a minimum of three independent litters derived from separate dams. Significant ANOVA results were followed by Tukey’s HSD test for multiple group comparisons where appropriate. All statistical tests were two-tailed with p&lt;0.05 considered significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>These studies were supported by grants from the National Institutes of Health (R01 NS086933-01, R01 AG 064465, T32 MH016880 and T32 AG052371) and funds from the Linda Crnic Institute. We thank Nicole Kethley, Michael Roche, Daniel Peterson, Stephanie Quintana, and Emily Schmitt for technical contributions to this work and Drs. Luke Evans and Peter Cain for useful comments and discussions in the preparation of the manuscript. We dedicate this work in the loving memory of Ms. Lauren LaPlante, our friend and colleague whose contributions were not only critical to this study but also to the well-being of our research group.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Supervision, Investigation</p></fn><fn fn-type="con" id="con4"><p>Supervision, Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Statistical analysis using t-tests.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56630-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Outliers and justification.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56630-supp2-v2.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Statistical analysis using ANOVAs.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56630-supp3-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-56630-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-9.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abel</surname> <given-names>KM</given-names></name><name><surname>Drake</surname> <given-names>R</given-names></name><name><surname>Goldstein</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sex differences in schizophrenia</article-title><source>International Review of Psychiatry</source><volume>22</volume><fpage>417</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.3109/09540261.2010.515205</pub-id><pub-id pub-id-type="pmid">21047156</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achim</surname> <given-names>AM</given-names></name><name><surname>Lepage</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Is associative recognition more impaired than item recognition memory in schizophrenia? A meta-analysis</article-title><source>Brain and Cognition</source><volume>53</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0278-2626(03)00092-7</pub-id><pub-id pub-id-type="pmid">14607130</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achim</surname> <given-names>AM</given-names></name><name><surname>Lepage</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Episodic memory-related activation in schizophrenia: meta-analysis</article-title><source>British Journal of Psychiatry</source><volume>187</volume><fpage>500</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1192/bjp.187.6.500</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname> <given-names>NG</given-names></name><name><surname>Weiel</surname> <given-names>JE</given-names></name><name><surname>Chan</surname> <given-names>CP</given-names></name><name><surname>Krebs</surname> <given-names>EG</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Identification of multiple epidermal growth factor-stimulated protein serine/threonine kinases from swiss 3t3 cells</article-title><source>The Journal of Biological Chemistry</source><volume>265</volume><fpage>11487</fpage><lpage>11494</lpage><pub-id pub-id-type="pmid">2142153</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberich</surname> <given-names>S</given-names></name><name><surname>Fernández-Sevillano</surname> <given-names>J</given-names></name><name><surname>González-Ortega</surname> <given-names>I</given-names></name><name><surname>Usall</surname> <given-names>J</given-names></name><name><surname>Sáenz</surname> <given-names>M</given-names></name><name><surname>González-Fraile</surname> <given-names>E</given-names></name><name><surname>González-Pinto</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A systematic review of sex-based differences in effectiveness and adverse effects of clozapine</article-title><source>Psychiatry Research</source><volume>280</volume><elocation-id>112506</elocation-id><pub-id pub-id-type="doi">10.1016/j.psychres.2019.112506</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert-Gascó</surname> <given-names>H</given-names></name><name><surname>Ros-Bernal</surname> <given-names>F</given-names></name><name><surname>Castillo-Gómez</surname> <given-names>E</given-names></name><name><surname>Olucha-Bordonau</surname> <given-names>FE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>4471</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21124471</pub-id><pub-id pub-id-type="pmid">32586047</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alimohamad</surname> <given-names>H</given-names></name><name><surname>Rajakumar</surname> <given-names>N</given-names></name><name><surname>Seah</surname> <given-names>Y-H</given-names></name><name><surname>Rushlow</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum</article-title><source>Biological Psychiatry</source><volume>57</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.036</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><year iso-8601-date="2013">2013</year><source>Diagnostic and Statistical Manual of Mental Disorders</source><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balu</surname> <given-names>DT</given-names></name><name><surname>Carlson</surname> <given-names>GC</given-names></name><name><surname>Talbot</surname> <given-names>K</given-names></name><name><surname>Kazi</surname> <given-names>H</given-names></name><name><surname>Hill-Smith</surname> <given-names>TE</given-names></name><name><surname>Easton</surname> <given-names>RM</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name><name><surname>Lucki</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function</article-title><source>Hippocampus</source><volume>22</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1002/hipo.20887</pub-id><pub-id pub-id-type="pmid">21049487</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname> <given-names>JM</given-names></name><name><surname>Sotnikova</surname> <given-names>TD</given-names></name><name><surname>Yao</surname> <given-names>WD</given-names></name><name><surname>Kockeritz</surname> <given-names>L</given-names></name><name><surname>Woodgett</surname> <given-names>JR</given-names></name><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade</article-title><source>PNAS</source><volume>101</volume><fpage>5099</fpage><lpage>5104</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307921101</pub-id><pub-id pub-id-type="pmid">15044694</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname> <given-names>J-M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Rodriguiz</surname> <given-names>RM</given-names></name><name><surname>Sotnikova</surname> <given-names>TD</given-names></name><name><surname>Cools</surname> <given-names>MJ</given-names></name><name><surname>Wetsel</surname> <given-names>WC</given-names></name><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Role of GSK3 in behavioral abnormalities induced by serotonin deficiency</article-title><source>PNAS</source><volume>105</volume><fpage>1333</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711496105</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname> <given-names>JM</given-names></name><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Akt/GSK3 signaling in the action of psychotropic drugs</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>49</volume><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.011008.145634</pub-id><pub-id pub-id-type="pmid">18928402</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname> <given-names>Y</given-names></name><name><surname>Bureau</surname> <given-names>G</given-names></name><name><surname>Laurier-Laurin</surname> <given-names>MÉ</given-names></name><name><surname>Asselin</surname> <given-names>E</given-names></name><name><surname>Massicotte</surname> <given-names>G</given-names></name><name><surname>Cyr</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic deletion of Akt3 induces an endophenotype reminiscent of psychiatric manifestations in mice</article-title><source>Frontiers in Molecular Neuroscience</source><volume>10</volume><elocation-id>102</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2017.00102</pub-id><pub-id pub-id-type="pmid">28442992</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasi</surname> <given-names>G</given-names></name><name><surname>Napolitano</surname> <given-names>F</given-names></name><name><surname>Ursini</surname> <given-names>G</given-names></name><name><surname>Taurisano</surname> <given-names>P</given-names></name><name><surname>Romano</surname> <given-names>R</given-names></name><name><surname>Caforio</surname> <given-names>G</given-names></name><name><surname>Fazio</surname> <given-names>L</given-names></name><name><surname>Gelao</surname> <given-names>B</given-names></name><name><surname>Di Giorgio</surname> <given-names>A</given-names></name><name><surname>Iacovelli</surname> <given-names>L</given-names></name><name><surname>Sinibaldi</surname> <given-names>L</given-names></name><name><surname>Popolizio</surname> <given-names>T</given-names></name><name><surname>Usiello</surname> <given-names>A</given-names></name><name><surname>Bertolino</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia</article-title><source>PNAS</source><volume>108</volume><fpage>1158</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1073/pnas.1013535108</pub-id><pub-id pub-id-type="pmid">21187413</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boks</surname> <given-names>MP</given-names></name><name><surname>Russo</surname> <given-names>S</given-names></name><name><surname>Knegtering</surname> <given-names>R</given-names></name><name><surname>van den Bosch</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The specificity of neurological signs in schizophrenia: a review</article-title><source>Schizophrenia Research</source><volume>43</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(99)00145-0</pub-id><pub-id pub-id-type="pmid">10858629</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwknecht</surname> <given-names>JA</given-names></name><name><surname>Paylor</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents</article-title><source>Behavioural Pharmacology</source><volume>19</volume><fpage>385</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1097/FBP.0b013e32830c3658</pub-id><pub-id pub-id-type="pmid">18690100</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussey</surname> <given-names>TJ</given-names></name><name><surname>Holmes</surname> <given-names>A</given-names></name><name><surname>Lyon</surname> <given-names>L</given-names></name><name><surname>Mar</surname> <given-names>AC</given-names></name><name><surname>McAllister</surname> <given-names>KA</given-names></name><name><surname>Nithianantharajah</surname> <given-names>J</given-names></name><name><surname>Oomen</surname> <given-names>CA</given-names></name><name><surname>Saksida</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats</article-title><source>Neuropharmacology</source><volume>62</volume><fpage>1191</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.04.011</pub-id><pub-id pub-id-type="pmid">21530550</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalecka-Franaszek</surname> <given-names>E</given-names></name><name><surname>Chuang</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons</article-title><source>PNAS</source><volume>96</volume><fpage>8745</fpage><lpage>8750</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.15.8745</pub-id><pub-id pub-id-type="pmid">10411946</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>C-Y</given-names></name><name><surname>Chen</surname> <given-names>Y-W</given-names></name><name><surname>Wang</surname> <given-names>T-W</given-names></name><name><surname>Lai</surname> <given-names>W-S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Akting up in the GABA hypothesis of schizophrenia: Akt1 deficiency modulates GABAergic functions and hippocampus-dependent functions</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>33095</elocation-id><pub-id pub-id-type="doi">10.1038/srep33095</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname> <given-names>H</given-names></name><name><surname>Thorvaldsen</surname> <given-names>JL</given-names></name><name><surname>Chu</surname> <given-names>Q</given-names></name><name><surname>Feng</surname> <given-names>F</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>38349</fpage><lpage>38352</lpage><pub-id pub-id-type="doi">10.1074/jbc.C100462200</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courtney</surname> <given-names>SM</given-names></name><name><surname>Petit</surname> <given-names>L</given-names></name><name><surname>Haxby</surname> <given-names>JV</given-names></name><name><surname>Ungerleider</surname> <given-names>LG</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The role of prefrontal cortex in working memory: examining the contents of consciousness</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>353</volume><fpage>1819</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1098/rstb.1998.0334</pub-id><pub-id pub-id-type="pmid">9854254</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craske</surname> <given-names>MG</given-names></name><name><surname>Hermans</surname> <given-names>D</given-names></name><name><surname>Vervliet</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>State-of-the-art and future directions for extinction as a translational model for fear and anxiety</article-title><source>Philosophical Transactions of the Royal Society B: Biological Sciences</source><volume>373</volume><elocation-id>20180432</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2018.0432</pub-id><pub-id pub-id-type="pmid">29352025</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname> <given-names>MB</given-names></name><name><surname>DeLisi</surname> <given-names>LE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Issues related to sex differences in antipsychotic treatment</article-title><source>Current Opinion in Psychiatry</source><volume>29</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1097/YCO.0000000000000243</pub-id><pub-id pub-id-type="pmid">26906336</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname> <given-names>DAE</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>Vandenheede</surname> <given-names>JR</given-names></name><name><surname>McDowell</surname> <given-names>HE</given-names></name><name><surname>Hundal</surname> <given-names>HS</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between ras and raf</article-title><source>Biochemical Journal</source><volume>303</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1042/bj3030021</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname> <given-names>DA</given-names></name><name><surname>Alessi</surname> <given-names>DR</given-names></name><name><surname>Cohen</surname> <given-names>P</given-names></name><name><surname>Andjelkovich</surname> <given-names>M</given-names></name><name><surname>Hemmings</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title><source>Nature</source><volume>378</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/378785a0</pub-id><pub-id pub-id-type="pmid">8524413</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sarno</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Jope</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium</article-title><source>Neuropharmacology</source><volume>43</volume><fpage>1158</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(02)00215-0</pub-id><pub-id pub-id-type="pmid">12504922</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delamater</surname> <given-names>AR</given-names></name><name><surname>Campese</surname> <given-names>V</given-names></name><name><surname>Westbrook</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Renewal and spontaneous recovery, but not latent inhibition, are mediated by gamma-aminobutyric acid in appetitive conditioning</article-title><source>Journal of Experimental Psychology: Animal Behavior Processes</source><volume>35</volume><fpage>224</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1037/a0013293</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname> <given-names>JC</given-names></name><name><surname>Ray</surname> <given-names>AK</given-names></name><name><surname>Gruber</surname> <given-names>RC</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Aflakpui</surname> <given-names>R</given-names></name><name><surname>Macian-Juan</surname> <given-names>F</given-names></name><name><surname>Shafit-Zagardo</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Akt3-Mediated protection against inflammatory demyelinating disease</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1738</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01738</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname> <given-names>RS</given-names></name><name><surname>Voleti</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents</article-title><source>Trends in Neurosciences</source><volume>35</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2011.11.004</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname> <given-names>RM</given-names></name><name><surname>Cho</surname> <given-names>H</given-names></name><name><surname>Roovers</surname> <given-names>K</given-names></name><name><surname>Shineman</surname> <given-names>DW</given-names></name><name><surname>Mizrahi</surname> <given-names>M</given-names></name><name><surname>Forman</surname> <given-names>MS</given-names></name><name><surname>Lee</surname> <given-names>VM-Y</given-names></name><name><surname>Szabolcs</surname> <given-names>M</given-names></name><name><surname>de Jong</surname> <given-names>R</given-names></name><name><surname>Oltersdorf</surname> <given-names>T</given-names></name><name><surname>Ludwig</surname> <given-names>T</given-names></name><name><surname>Efstratiadis</surname> <given-names>A</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role for Akt3/Protein kinase bγ in attainment of normal brain size</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>1869</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.5.1869-1878.2005</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname> <given-names>R</given-names></name><name><surname>Baker</surname> <given-names>SC</given-names></name><name><surname>Rogers</surname> <given-names>RD</given-names></name><name><surname>O'Leary</surname> <given-names>DA</given-names></name><name><surname>Paykel</surname> <given-names>ES</given-names></name><name><surname>Frith</surname> <given-names>CD</given-names></name><name><surname>Dolan</surname> <given-names>RJ</given-names></name><name><surname>Sahakian</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Prefrontal dysfunction in depressed patients performing a complex planning task: a study using positron emission tomography</article-title><source>Psychological Medicine</source><volume>27</volume><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1017/S0033291797005187</pub-id><pub-id pub-id-type="pmid">9234470</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellsworth</surname> <given-names>KA</given-names></name><name><surname>Moon</surname> <given-names>I</given-names></name><name><surname>Eckloff</surname> <given-names>BW</given-names></name><name><surname>Fridley</surname> <given-names>BL</given-names></name><name><surname>Jenkins</surname> <given-names>GD</given-names></name><name><surname>Batzler</surname> <given-names>A</given-names></name><name><surname>Biernacka</surname> <given-names>JM</given-names></name><name><surname>Abo</surname> <given-names>R</given-names></name><name><surname>Brisbin</surname> <given-names>A</given-names></name><name><surname>Ji</surname> <given-names>Y</given-names></name><name><surname>Hebbring</surname> <given-names>S</given-names></name><name><surname>Wieben</surname> <given-names>ED</given-names></name><name><surname>Mrazek</surname> <given-names>DA</given-names></name><name><surname>Weinshilboum</surname> <given-names>RM</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder</article-title><source>Pharmacogenetics and Genomics</source><volume>23</volume><fpage>156</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e32835dc133</pub-id><pub-id pub-id-type="pmid">23324805</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emamian</surname> <given-names>ES</given-names></name><name><surname>Hall</surname> <given-names>D</given-names></name><name><surname>Birnbaum</surname> <given-names>MJ</given-names></name><name><surname>Karayiorgou</surname> <given-names>M</given-names></name><name><surname>Gogos</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia</article-title><source>Nature Genetics</source><volume>36</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1038/ng1296</pub-id><pub-id pub-id-type="pmid">14745448</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallgatter</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Electrophysiology of the prefrontal cortex in healthy controls and schizophrenic patients: a review</article-title><source>Journal of Neural Transmission</source><volume>108</volume><fpage>679</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1007/s007020170045</pub-id><pub-id pub-id-type="pmid">11478420</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname> <given-names>MS</given-names></name><name><surname>Werge</surname> <given-names>T</given-names></name><name><surname>Sklar</surname> <given-names>P</given-names></name><name><surname>Owen</surname> <given-names>MJ</given-names></name><name><surname>Ophoff</surname> <given-names>RA</given-names></name><name><surname>O'Donovan</surname> <given-names>MC</given-names></name><name><surname>Corvin</surname> <given-names>A</given-names></name><name><surname>Cichon</surname> <given-names>S</given-names></name><name><surname>Sullivan</surname> <given-names>PF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Evaluating historical candidate genes for schizophrenia</article-title><source>Molecular Psychiatry</source><volume>20</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/mp.2015.16</pub-id><pub-id pub-id-type="pmid">25754081</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschelli</surname> <given-names>A</given-names></name><name><surname>Sens</surname> <given-names>J</given-names></name><name><surname>Herchick</surname> <given-names>S</given-names></name><name><surname>Thelen</surname> <given-names>C</given-names></name><name><surname>Pitychoutis</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and &quot;depressed&quot; mice exposed to chronic mild stress</article-title><source>Neuroscience</source><volume>290</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.01.008</pub-id><pub-id pub-id-type="pmid">25595985</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname> <given-names>TF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Intracellular signaling by akt: bound to be specific</article-title><source>Science Signaling</source><volume>1</volume><elocation-id>pe29</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.124pe29</pub-id><pub-id pub-id-type="pmid">18560018</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Franklin</surname> <given-names>KBJ</given-names></name><name><surname>Paxinos</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><edition>3rd Edition</edition><source>The Mouse Brain in Stereotaxic Coordinates</source><publisher-name>Academic Press.</publisher-name></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname> <given-names>TD</given-names></name><name><surname>Einat</surname> <given-names>H</given-names></name><name><surname>O'Donnell</surname> <given-names>KC</given-names></name><name><surname>Picchini</surname> <given-names>AM</given-names></name><name><surname>Schloesser</surname> <given-names>RJ</given-names></name><name><surname>Manji</surname> <given-names>HK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors</article-title><source>Neuropsychopharmacology</source><volume>32</volume><fpage>2173</fpage><lpage>2183</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301338</pub-id><pub-id pub-id-type="pmid">17299510</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname> <given-names>RJ</given-names></name><name><surname>Moloney</surname> <given-names>A</given-names></name><name><surname>Kelliher</surname> <given-names>M</given-names></name><name><surname>Johnston</surname> <given-names>JA</given-names></name><name><surname>Ravid</surname> <given-names>R</given-names></name><name><surname>Dockery</surname> <given-names>P</given-names></name><name><surname>O'Connor</surname> <given-names>R</given-names></name><name><surname>O'Neill</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation of akt/PKB, increased phosphorylation of akt substrates and loss and altered distribution of akt and PTEN are features of alzheimer's disease pathology</article-title><source>Journal of Neurochemistry</source><volume>93</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02949.x</pub-id><pub-id pub-id-type="pmid">15773910</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Häfner</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gender differences in schizophrenia</article-title><source>Psychoneuroendocrinology</source><volume>28 Suppl 2</volume><fpage>17</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S0306-4530(02)00125-7</pub-id><pub-id pub-id-type="pmid">12650680</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeffer</surname> <given-names>CA</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Wong</surname> <given-names>H</given-names></name><name><surname>Santillan</surname> <given-names>A</given-names></name><name><surname>Patterson</surname> <given-names>RJ</given-names></name><name><surname>Martinez</surname> <given-names>LA</given-names></name><name><surname>Tejada-Simon</surname> <given-names>MV</given-names></name><name><surname>Paylor</surname> <given-names>R</given-names></name><name><surname>Hamilton</surname> <given-names>SL</given-names></name><name><surname>Klann</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior</article-title><source>Neuron</source><volume>60</volume><fpage>832</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.09.037</pub-id><pub-id pub-id-type="pmid">19081378</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeffer</surname> <given-names>CA</given-names></name><name><surname>Wong</surname> <given-names>H</given-names></name><name><surname>Cain</surname> <given-names>P</given-names></name><name><surname>Levenga</surname> <given-names>J</given-names></name><name><surname>Cowansage</surname> <given-names>KK</given-names></name><name><surname>Choi</surname> <given-names>Y</given-names></name><name><surname>Davy</surname> <given-names>C</given-names></name><name><surname>Majmundar</surname> <given-names>N</given-names></name><name><surname>McMillan</surname> <given-names>DR</given-names></name><name><surname>Rothermel</surname> <given-names>BA</given-names></name><name><surname>Klann</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>16930</fpage><lpage>16944</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3513-12.2013</pub-id><pub-id pub-id-type="pmid">24155299</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeffer</surname> <given-names>CA</given-names></name><name><surname>Klann</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>mTOR signaling: at the crossroads of plasticity, memory and disease</article-title><source>Trends in Neurosciences</source><volume>33</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2009.11.003</pub-id><pub-id pub-id-type="pmid">19963289</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname> <given-names>KR</given-names></name><name><surname>Floyd</surname> <given-names>K</given-names></name><name><surname>Law</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PKBγ/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: relevance for schizophrenia</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0175993</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0175993</pub-id><pub-id pub-id-type="pmid">28467426</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiung</surname> <given-names>SC</given-names></name><name><surname>Adlersberg</surname> <given-names>M</given-names></name><name><surname>Arango</surname> <given-names>V</given-names></name><name><surname>Mann</surname> <given-names>JJ</given-names></name><name><surname>Tamir</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, akt and mitogen-activated protein kinase</article-title><source>Journal of Neurochemistry</source><volume>87</volume><fpage>182</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01987.x</pub-id><pub-id pub-id-type="pmid">12969265</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutz</surname> <given-names>JE</given-names></name><name><surname>Manning</surname> <given-names>WA</given-names></name><name><surname>Province</surname> <given-names>MA</given-names></name><name><surname>McLeod</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e24873</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024873</pub-id><pub-id pub-id-type="pmid">21949775</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname> <given-names>M</given-names></name><name><surname>Iwata</surname> <given-names>N</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Kitajima</surname> <given-names>T</given-names></name><name><surname>Yamanouchi</surname> <given-names>Y</given-names></name><name><surname>Kinoshita</surname> <given-names>Y</given-names></name><name><surname>Inada</surname> <given-names>T</given-names></name><name><surname>Ozaki</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Association of AKT1 with schizophrenia confirmed in a japanese population</article-title><source>Biological Psychiatry</source><volume>56</volume><fpage>698</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.07.023</pub-id><pub-id pub-id-type="pmid">15522255</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagannathan</surname> <given-names>K</given-names></name><name><surname>Calhoun</surname> <given-names>VD</given-names></name><name><surname>Gelernter</surname> <given-names>J</given-names></name><name><surname>Stevens</surname> <given-names>MC</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Bolognani</surname> <given-names>F</given-names></name><name><surname>Windemuth</surname> <given-names>A</given-names></name><name><surname>Ruaño</surname> <given-names>G</given-names></name><name><surname>Assaf</surname> <given-names>M</given-names></name><name><surname>Pearlson</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic associations of brain structural networks in schizophrenia: a preliminary study</article-title><source>Biological Psychiatry</source><volume>68</volume><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.06.002</pub-id><pub-id pub-id-type="pmid">20691427</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>EC</given-names></name><name><surname>Border</surname> <given-names>R</given-names></name><name><surname>Melroy-Greif</surname> <given-names>WE</given-names></name><name><surname>de Leeuw</surname> <given-names>CA</given-names></name><name><surname>Ehringer</surname> <given-names>MA</given-names></name><name><surname>Keller</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>No evidence that schizophrenia candidate genes are more associated with schizophrenia than noncandidate genes</article-title><source>Biological Psychiatry</source><volume>82</volume><fpage>702</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2017.06.033</pub-id><pub-id pub-id-type="pmid">28823710</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>DM</given-names></name><name><surname>Tucker</surname> <given-names>BA</given-names></name><name><surname>Rahimtula</surname> <given-names>M</given-names></name><name><surname>Mearow</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The synergistic effects of NGF and IGF-1 on neurite growth in adult sensory neurons: convergence on the PI 3-kinase signaling pathway</article-title><source>Journal of Neurochemistry</source><volume>86</volume><fpage>1116</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01925.x</pub-id><pub-id pub-id-type="pmid">12911620</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandel</surname> <given-names>ES</given-names></name><name><surname>Hay</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The regulation and activities of the multifunctional serine/threonine kinase akt/PKB</article-title><source>Experimental Cell Research</source><volume>253</volume><fpage>210</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1006/excr.1999.4690</pub-id><pub-id pub-id-type="pmid">10579924</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karege</surname> <given-names>F</given-names></name><name><surname>Perroud</surname> <given-names>N</given-names></name><name><surname>Schürhoff</surname> <given-names>F</given-names></name><name><surname>Méary</surname> <given-names>A</given-names></name><name><surname>Marillier</surname> <given-names>G</given-names></name><name><surname>Burkhardt</surname> <given-names>S</given-names></name><name><surname>Ballmann</surname> <given-names>E</given-names></name><name><surname>Fernandez</surname> <given-names>R</given-names></name><name><surname>Jamain</surname> <given-names>S</given-names></name><name><surname>Leboyer</surname> <given-names>M</given-names></name><name><surname>La Harpe</surname> <given-names>R</given-names></name><name><surname>Malafosse</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder</article-title><source>Genes, Brain, and Behavior</source><volume>9</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2010.00578.x</pub-id><pub-id pub-id-type="pmid">20214684</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karege</surname> <given-names>F</given-names></name><name><surname>Méary</surname> <given-names>A</given-names></name><name><surname>Perroud</surname> <given-names>N</given-names></name><name><surname>Jamain</surname> <given-names>S</given-names></name><name><surname>Leboyer</surname> <given-names>M</given-names></name><name><surname>Ballmann</surname> <given-names>E</given-names></name><name><surname>Fernandez</surname> <given-names>R</given-names></name><name><surname>Malafosse</surname> <given-names>A</given-names></name><name><surname>Schürhoff</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetic overlap between schizophrenia and bipolar disorder: a study with AKT1 gene variants and clinical phenotypes</article-title><source>Schizophrenia Research</source><volume>135</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2011.12.015</pub-id><pub-id pub-id-type="pmid">22277669</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keers</surname> <given-names>R</given-names></name><name><surname>Aitchison</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gender differences in antidepressant drug response</article-title><source>International Review of Psychiatry</source><volume>22</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.3109/09540261.2010.496448</pub-id><pub-id pub-id-type="pmid">21047161</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname> <given-names>RC</given-names></name><name><surname>McGonagle</surname> <given-names>KA</given-names></name><name><surname>Swartz</surname> <given-names>M</given-names></name><name><surname>Blazer</surname> <given-names>DG</given-names></name><name><surname>Nelson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Sex and depression in the national comorbidity survey I: lifetime prevalence, chronicity and recurrence</article-title><source>Journal of Affective Disorders</source><volume>29</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/0165-0327(93)90026-G</pub-id><pub-id pub-id-type="pmid">8300981</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname> <given-names>RC</given-names></name><name><surname>Chiu</surname> <given-names>WT</given-names></name><name><surname>Demler</surname> <given-names>O</given-names></name><name><surname>Merikangas</surname> <given-names>KR</given-names></name><name><surname>Walters</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication</article-title><source>Archives of General Psychiatry</source><volume>62</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.62.6.617</pub-id><pub-id pub-id-type="pmid">15939839</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>MH</given-names></name><name><surname>Mazei-Robison</surname> <given-names>M</given-names></name><name><surname>Iñiguez</surname> <given-names>SD</given-names></name><name><surname>Ables</surname> <given-names>JL</given-names></name><name><surname>Vialou</surname> <given-names>V</given-names></name><name><surname>Berton</surname> <given-names>O</given-names></name><name><surname>Ghose</surname> <given-names>S</given-names></name><name><surname>Covington</surname> <given-names>HE</given-names></name><name><surname>Wiley</surname> <given-names>MD</given-names></name><name><surname>Henderson</surname> <given-names>RP</given-names></name><name><surname>Neve</surname> <given-names>RL</given-names></name><name><surname>Eisch</surname> <given-names>AJ</given-names></name><name><surname>Tamminga</surname> <given-names>CA</given-names></name><name><surname>Russo</surname> <given-names>SJ</given-names></name><name><surname>Bolaños</surname> <given-names>CA</given-names></name><name><surname>Nestler</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli</article-title><source>Biological Psychiatry</source><volume>64</volume><fpage>691</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2008.06.003</pub-id><pub-id pub-id-type="pmid">18639865</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibrock</surname> <given-names>C</given-names></name><name><surname>Ackermann</surname> <given-names>TF</given-names></name><name><surname>Hierlmeier</surname> <given-names>M</given-names></name><name><surname>Lang</surname> <given-names>F</given-names></name><name><surname>Borgwardt</surname> <given-names>S</given-names></name><name><surname>Lang</surname> <given-names>UE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Akt2 deficiency is associated with anxiety and depressive behavior in mice</article-title><source>Cellular Physiology and Biochemistry</source><volume>32</volume><fpage>766</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1159/000354478</pub-id><pub-id pub-id-type="pmid">24080829</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levenga</surname> <given-names>J</given-names></name><name><surname>Wong</surname> <given-names>H</given-names></name><name><surname>Milstead</surname> <given-names>RA</given-names></name><name><surname>Keller</surname> <given-names>BN</given-names></name><name><surname>LaPlante</surname> <given-names>LE</given-names></name><name><surname>Hoeffer</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>AKT isoforms have distinct hippocampal expression and roles in synaptic plasticity</article-title><source>eLife</source><volume>6</volume><elocation-id>e30640</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.30640</pub-id><pub-id pub-id-type="pmid">29173281</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Roh</surname> <given-names>MS</given-names></name><name><surname>Friedman</surname> <given-names>AB</given-names></name><name><surname>Rosborough</surname> <given-names>K</given-names></name><name><surname>Jope</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain</article-title><source>Neuropsychopharmacology</source><volume>29</volume><fpage>1426</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300439</pub-id><pub-id pub-id-type="pmid">15039769</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Rosborough</surname> <given-names>KM</given-names></name><name><surname>Friedman</surname> <given-names>AB</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Roth</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics</article-title><source>The International Journal of Neuropsychopharmacology</source><volume>10</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1017/S1461145706006547</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>RJ</given-names></name><name><surname>Banasr</surname> <given-names>M</given-names></name><name><surname>Dwyer</surname> <given-names>JM</given-names></name><name><surname>Iwata</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>XY</given-names></name><name><surname>Aghajanian</surname> <given-names>G</given-names></name><name><surname>Duman</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</article-title><source>Science</source><volume>329</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1126/science.1190287</pub-id><pub-id pub-id-type="pmid">20724638</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Deng</surname> <given-names>Y</given-names></name><name><surname>Yi</surname> <given-names>Z</given-names></name><name><surname>Shi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis</article-title><source>BMC Medical Genomics</source><volume>6 Suppl 1</volume><elocation-id>S17</elocation-id><pub-id pub-id-type="doi">10.1186/1755-8794-6-S1-S17</pub-id><pub-id pub-id-type="pmid">23369358</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname> <given-names>HC</given-names></name><name><surname>Chow</surname> <given-names>TJ</given-names></name><name><surname>Tang</surname> <given-names>PY</given-names></name><name><surname>Yong</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>No association between AKT1 gene variants and schizophrenia: a malaysian case-control study and meta-analysis</article-title><source>Psychiatry Research</source><volume>209</volume><fpage>732</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2013.05.017</pub-id><pub-id pub-id-type="pmid">23747160</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeng</surname> <given-names>LY</given-names></name><name><surname>Milad</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sex differences in anxiety disorders: interactions between fear, stress, and gonadal hormones</article-title><source>Hormones and Behavior</source><volume>76</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2015.04.002</pub-id><pub-id pub-id-type="pmid">25888456</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maren</surname> <given-names>S</given-names></name><name><surname>Phan</surname> <given-names>KL</given-names></name><name><surname>Liberzon</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The contextual brain: implications for fear conditioning, extinction and psychopathology</article-title><source>Nature Reviews Neuroscience</source><volume>14</volume><fpage>417</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1038/nrn3492</pub-id><pub-id pub-id-type="pmid">23635870</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maren</surname> <given-names>S</given-names></name><name><surname>Holmes</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stress and fear extinction</article-title><source>Neuropsychopharmacology</source><volume>41</volume><fpage>58</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/npp.2015.180</pub-id><pub-id pub-id-type="pmid">26105142</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meesters</surname> <given-names>PD</given-names></name><name><surname>de Haan</surname> <given-names>L</given-names></name><name><surname>Comijs</surname> <given-names>HC</given-names></name><name><surname>Stek</surname> <given-names>ML</given-names></name><name><surname>Smeets-Janssen</surname> <given-names>MMJ</given-names></name><name><surname>Weeda</surname> <given-names>MR</given-names></name><name><surname>Eikelenboom</surname> <given-names>P</given-names></name><name><surname>Smit</surname> <given-names>JH</given-names></name><name><surname>Beekman</surname> <given-names>ATF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area</article-title><source>The American Journal of Geriatric Psychiatry</source><volume>20</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/JGP.0b013e3182011b7f</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Developments of a water-maze procedure for studying spatial learning in the rat</article-title><source>Journal of Neuroscience Methods</source><volume>11</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(84)90007-4</pub-id><pub-id pub-id-type="pmid">6471907</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musci</surname> <given-names>RJ</given-names></name><name><surname>Augustinavicius</surname> <given-names>JL</given-names></name><name><surname>Volk</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gene-Environment interactions in psychiatry: recent evidence and clinical implications</article-title><source>Current Psychiatry Reports</source><volume>21</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1007/s11920-019-1065-5</pub-id><pub-id pub-id-type="pmid">31410638</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nciri</surname> <given-names>R</given-names></name><name><surname>Desmoulin</surname> <given-names>F</given-names></name><name><surname>Allagui</surname> <given-names>MS</given-names></name><name><surname>Murat</surname> <given-names>J-C</given-names></name><name><surname>Feki</surname> <given-names>AE</given-names></name><name><surname>Vincent</surname> <given-names>C</given-names></name><name><surname>Croute</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress</article-title><source>International Journal of Neuropsychopharmacology</source><volume>16</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1017/S1461145712000132</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicodemus</surname> <given-names>KK</given-names></name><name><surname>Law</surname> <given-names>AJ</given-names></name><name><surname>Radulescu</surname> <given-names>E</given-names></name><name><surname>Luna</surname> <given-names>A</given-names></name><name><surname>Kolachana</surname> <given-names>B</given-names></name><name><surname>Vakkalanka</surname> <given-names>R</given-names></name><name><surname>Rujescu</surname> <given-names>D</given-names></name><name><surname>Giegling</surname> <given-names>I</given-names></name><name><surname>Straub</surname> <given-names>RE</given-names></name><name><surname>McGee</surname> <given-names>K</given-names></name><name><surname>Gold</surname> <given-names>B</given-names></name><name><surname>Dean</surname> <given-names>M</given-names></name><name><surname>Muglia</surname> <given-names>P</given-names></name><name><surname>Callicott</surname> <given-names>JH</given-names></name><name><surname>Tan</surname> <given-names>HY</given-names></name><name><surname>Weinberger</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls</article-title><source>Archives of General Psychiatry</source><volume>67</volume><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.117</pub-id><pub-id pub-id-type="pmid">20921115</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>SW</given-names></name><name><surname>Lee</surname> <given-names>JG</given-names></name><name><surname>Seo</surname> <given-names>MK</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Cho</surname> <given-names>HY</given-names></name><name><surname>Lee</surname> <given-names>BJ</given-names></name><name><surname>Seol</surname> <given-names>W</given-names></name><name><surname>Kim</surname> <given-names>YH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons</article-title><source>The International Journal of Neuropsychopharmacology</source><volume>17</volume><fpage>1831</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1017/S1461145714000534</pub-id><pub-id pub-id-type="pmid">24901414</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname> <given-names>DM</given-names></name><name><surname>Rossomando</surname> <given-names>AJ</given-names></name><name><surname>Martino</surname> <given-names>P</given-names></name><name><surname>Erickson</surname> <given-names>AK</given-names></name><name><surname>Her</surname> <given-names>JH</given-names></name><name><surname>Shabanowitz</surname> <given-names>J</given-names></name><name><surname>Hunt</surname> <given-names>DF</given-names></name><name><surname>Weber</surname> <given-names>MJ</given-names></name><name><surname>Sturgill</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase)</article-title><source>The EMBO Journal</source><volume>10</volume><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb08021.x</pub-id><pub-id pub-id-type="pmid">1849075</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname> <given-names>PA</given-names></name><name><surname>Bicalho</surname> <given-names>MA</given-names></name><name><surname>de Moraes</surname> <given-names>EN</given-names></name><name><surname>Malloy-Diniz</surname> <given-names>L</given-names></name><name><surname>Bozzi</surname> <given-names>IC</given-names></name><name><surname>Nicolato</surname> <given-names>R</given-names></name><name><surname>Valadão</surname> <given-names>DR</given-names></name><name><surname>Miranda</surname> <given-names>DM</given-names></name><name><surname>Romano-Silva</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic variant of <italic>AKT1</italic> and <italic>AKTIP</italic> associated with late-onset depression in a brazilian population</article-title><source>International Journal of Geriatric Psychiatry</source><volume>29</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/gps.4018</pub-id><pub-id pub-id-type="pmid">24022875</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkinton</surname> <given-names>MS</given-names></name><name><surname>Ip</surname> <given-names>JK</given-names></name><name><surname>Wood</surname> <given-names>GL</given-names></name><name><surname>Crossthwaite</surname> <given-names>AJ</given-names></name><name><surname>Williams</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones</article-title><source>Journal of Neurochemistry</source><volume>80</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1046/j.0022-3042.2001.00699.x</pub-id><pub-id pub-id-type="pmid">11902114</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>MB</given-names></name><name><surname>de Kleine</surname> <given-names>RA</given-names></name><name><surname>Smits</surname> <given-names>JAJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Core mechanisms of cognitive behavioral therapy for anxiety and depression</article-title><source>Psychiatric Clinics of North America</source><volume>40</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.psc.2017.08.010</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Psychosis Endophenotypes International Consortium</collab><collab>Wellcome Trust Case-Control Consortium 2</collab><collab>Psychiatric Genomics Consortium</collab><name><surname>Bramon</surname> <given-names>E</given-names></name><name><surname>Pirinen</surname> <given-names>M</given-names></name><name><surname>Strange</surname> <given-names>A</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>Freeman</surname> <given-names>C</given-names></name><name><surname>Bellenguez</surname> <given-names>C</given-names></name><name><surname>Su</surname> <given-names>Z</given-names></name><name><surname>Band</surname> <given-names>G</given-names></name><name><surname>Pearson</surname> <given-names>R</given-names></name><name><surname>Vukcevic</surname> <given-names>D</given-names></name><name><surname>Langford</surname> <given-names>C</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Hunt</surname> <given-names>S</given-names></name><name><surname>Gray</surname> <given-names>E</given-names></name><name><surname>Dronov</surname> <given-names>S</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Tashakkori-Ghanbaria</surname> <given-names>A</given-names></name><name><surname>Edkins</surname> <given-names>S</given-names></name><name><surname>Bumpstead</surname> <given-names>SJ</given-names></name><name><surname>Arranz</surname> <given-names>MJ</given-names></name><name><surname>Bakker</surname> <given-names>S</given-names></name><name><surname>Bender</surname> <given-names>S</given-names></name><name><surname>Bruggeman</surname> <given-names>R</given-names></name><name><surname>Cahn</surname> <given-names>W</given-names></name><name><surname>Chandler</surname> <given-names>D</given-names></name><name><surname>Collier</surname> <given-names>DA</given-names></name><name><surname>Crespo-Facorro</surname> <given-names>B</given-names></name><name><surname>Dazzan</surname> <given-names>P</given-names></name><name><surname>de Haan</surname> <given-names>L</given-names></name><name><surname>Di Forti</surname> <given-names>M</given-names></name><name><surname>Dragović</surname> <given-names>M</given-names></name><name><surname>Giegling</surname> <given-names>I</given-names></name><name><surname>Hall</surname> <given-names>J</given-names></name><name><surname>Iyegbe</surname> <given-names>C</given-names></name><name><surname>Jablensky</surname> <given-names>A</given-names></name><name><surname>Kahn</surname> <given-names>RS</given-names></name><name><surname>Kalaydjieva</surname> <given-names>L</given-names></name><name><surname>Kravariti</surname> <given-names>E</given-names></name><name><surname>Lawrie</surname> <given-names>S</given-names></name><name><surname>Linszen</surname> <given-names>DH</given-names></name><name><surname>Mata</surname> <given-names>I</given-names></name><name><surname>McDonald</surname> <given-names>C</given-names></name><name><surname>McIntosh</surname> <given-names>A</given-names></name><name><surname>Myin-Germeys</surname> <given-names>I</given-names></name><name><surname>Ophoff</surname> <given-names>RA</given-names></name><name><surname>Pariante</surname> <given-names>CM</given-names></name><name><surname>Paunio</surname> <given-names>T</given-names></name><name><surname>Picchioni</surname> <given-names>M</given-names></name><name><surname>Ripke</surname> <given-names>S</given-names></name><name><surname>Rujescu</surname> <given-names>D</given-names></name><name><surname>Sauer</surname> <given-names>H</given-names></name><name><surname>Shaikh</surname> <given-names>M</given-names></name><name><surname>Sussmann</surname> <given-names>J</given-names></name><name><surname>Suvisaari</surname> <given-names>J</given-names></name><name><surname>Tosato</surname> <given-names>S</given-names></name><name><surname>Toulopoulou</surname> <given-names>T</given-names></name><name><surname>Van Os</surname> <given-names>J</given-names></name><name><surname>Walshe</surname> <given-names>M</given-names></name><name><surname>Weisbrod</surname> <given-names>M</given-names></name><name><surname>Whalley</surname> <given-names>H</given-names></name><name><surname>Wiersma</surname> <given-names>D</given-names></name><name><surname>Blackwell</surname> <given-names>JM</given-names></name><name><surname>Brown</surname> <given-names>MA</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><name><surname>Corvin</surname> <given-names>A</given-names></name><name><surname>Duncanson</surname> <given-names>A</given-names></name><name><surname>Jankowski</surname> <given-names>JA</given-names></name><name><surname>Markus</surname> <given-names>HS</given-names></name><name><surname>Mathew</surname> <given-names>CG</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Plomin</surname> <given-names>R</given-names></name><name><surname>Rautanen</surname> <given-names>A</given-names></name><name><surname>Sawcer</surname> <given-names>SJ</given-names></name><name><surname>Trembath</surname> <given-names>RC</given-names></name><name><surname>Wood</surname> <given-names>NW</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Peltonen</surname> <given-names>L</given-names></name><name><surname>Lewis</surname> <given-names>CM</given-names></name><name><surname>Murray</surname> <given-names>RM</given-names></name><name><surname>Donnelly</surname> <given-names>P</given-names></name><name><surname>Powell</surname> <given-names>J</given-names></name><name><surname>Spencer</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation</article-title><source>Biological Psychiatry</source><volume>75</volume><fpage>386</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.03.033</pub-id><pub-id pub-id-type="pmid">23871474</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname> <given-names>SM</given-names></name><name><surname>Moran</surname> <given-names>JL</given-names></name><name><surname>Fromer</surname> <given-names>M</given-names></name><name><surname>Ruderfer</surname> <given-names>D</given-names></name><name><surname>Solovieff</surname> <given-names>N</given-names></name><name><surname>Roussos</surname> <given-names>P</given-names></name><name><surname>O'Dushlaine</surname> <given-names>C</given-names></name><name><surname>Chambert</surname> <given-names>K</given-names></name><name><surname>Bergen</surname> <given-names>SE</given-names></name><name><surname>Kähler</surname> <given-names>A</given-names></name><name><surname>Duncan</surname> <given-names>L</given-names></name><name><surname>Stahl</surname> <given-names>E</given-names></name><name><surname>Genovese</surname> <given-names>G</given-names></name><name><surname>Fernández</surname> <given-names>E</given-names></name><name><surname>Collins</surname> <given-names>MO</given-names></name><name><surname>Komiyama</surname> <given-names>NH</given-names></name><name><surname>Choudhary</surname> <given-names>JS</given-names></name><name><surname>Magnusson</surname> <given-names>PK</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Shakir</surname> <given-names>K</given-names></name><name><surname>Garimella</surname> <given-names>K</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>DePristo</surname> <given-names>M</given-names></name><name><surname>Grant</surname> <given-names>SG</given-names></name><name><surname>Haggarty</surname> <given-names>SJ</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Scolnick</surname> <given-names>EM</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Hultman</surname> <given-names>CM</given-names></name><name><surname>Sullivan</surname> <given-names>PF</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Sklar</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title><source>Nature</source><volume>506</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature12975</pub-id><pub-id pub-id-type="pmid">24463508</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radulovic</surname> <given-names>J</given-names></name><name><surname>Tronson</surname> <given-names>NC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular specificity of multiple hippocampal processes governing fear extinction</article-title><source>Reviews in the Neurosciences</source><volume>21</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1515/REVNEURO.2010.21.1.1</pub-id><pub-id pub-id-type="pmid">20458884</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragland</surname> <given-names>JD</given-names></name><name><surname>Ranganath</surname> <given-names>C</given-names></name><name><surname>Harms</surname> <given-names>MP</given-names></name><name><surname>Barch</surname> <given-names>DM</given-names></name><name><surname>Gold</surname> <given-names>JM</given-names></name><name><surname>Layher</surname> <given-names>E</given-names></name><name><surname>Lesh</surname> <given-names>TA</given-names></name><name><surname>MacDonald</surname> <given-names>AW</given-names></name><name><surname>Niendam</surname> <given-names>TA</given-names></name><name><surname>Phillips</surname> <given-names>J</given-names></name><name><surname>Silverstein</surname> <given-names>SM</given-names></name><name><surname>Yonelinas</surname> <given-names>AP</given-names></name><name><surname>Carter</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and Item-Specific encoding task</article-title><source>JAMA Psychiatry</source><volume>72</volume><fpage>909</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.0276</pub-id><pub-id pub-id-type="pmid">26200928</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renoir</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>New frontiers in the neuropsychopharmacology of mental illness</article-title><source>Frontiers in Pharmacology</source><volume>5</volume><elocation-id>212</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00212</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinow</surname> <given-names>DR</given-names></name><name><surname>Schmidt</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sex differences and the neurobiology of affective disorders</article-title><source>Neuropsychopharmacology</source><volume>44</volume><fpage>111</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/s41386-018-0148-z</pub-id><pub-id pub-id-type="pmid">30061743</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saudou</surname> <given-names>F</given-names></name><name><surname>Finkbeiner</surname> <given-names>S</given-names></name><name><surname>Devys</surname> <given-names>D</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions</article-title><source>Cell</source><volume>95</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81782-1</pub-id><pub-id pub-id-type="pmid">9778247</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname> <given-names>MP</given-names></name><name><surname>Parsons</surname> <given-names>M</given-names></name><name><surname>Woodgett</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>2347</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.6.2347-2363.2005</pub-id><pub-id pub-id-type="pmid">15743829</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname> <given-names>J</given-names></name><name><surname>Kristensen</surname> <given-names>AS</given-names></name><name><surname>Wendland</surname> <given-names>JR</given-names></name><name><surname>Nöthen</surname> <given-names>MM</given-names></name><name><surname>Mors</surname> <given-names>O</given-names></name><name><surname>McMahon</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The genetics of panic disorder</article-title><source>Journal of Medical Genetics</source><volume>48</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1136/jmg.2010.086876</pub-id><pub-id pub-id-type="pmid">21493958</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname> <given-names>SG</given-names></name><name><surname>Hoefgen</surname> <given-names>B</given-names></name><name><surname>Hanses</surname> <given-names>C</given-names></name><name><surname>Hassenbach</surname> <given-names>MB</given-names></name><name><surname>Albus</surname> <given-names>M</given-names></name><name><surname>Lerer</surname> <given-names>B</given-names></name><name><surname>Trixler</surname> <given-names>M</given-names></name><name><surname>Maier</surname> <given-names>W</given-names></name><name><surname>Wildenauer</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of european sib-pair families</article-title><source>Biological Psychiatry</source><volume>58</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.05.005</pub-id><pub-id pub-id-type="pmid">16026766</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeman</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Treating schizophrenia at the time of menopause</article-title><source>Maturitas</source><volume>72</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2012.03.008</pub-id><pub-id pub-id-type="pmid">22503514</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname> <given-names>PF</given-names></name><name><surname>Kendler</surname> <given-names>KS</given-names></name><name><surname>Neale</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies</article-title><source>Archives of General Psychiatry</source><volume>60</volume><fpage>1187</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.60.12.1187</pub-id><pub-id pub-id-type="pmid">14662550</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname> <given-names>G</given-names></name><name><surname>Chandler</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Activity-dependent NMDA receptor-mediated activation of protein kinase B/Akt in cortical neuronal cultures</article-title><source>Journal of Neurochemistry</source><volume>82</volume><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01031.x</pub-id><pub-id pub-id-type="pmid">12358757</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>HY</given-names></name><name><surname>Nicodemus</surname> <given-names>KK</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Brooke</surname> <given-names>JK</given-names></name><name><surname>Honea</surname> <given-names>R</given-names></name><name><surname>Kolachana</surname> <given-names>BS</given-names></name><name><surname>Straub</surname> <given-names>RE</given-names></name><name><surname>Meyer-Lindenberg</surname> <given-names>A</given-names></name><name><surname>Sei</surname> <given-names>Y</given-names></name><name><surname>Mattay</surname> <given-names>VS</given-names></name><name><surname>Callicott</surname> <given-names>JH</given-names></name><name><surname>Weinberger</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans</article-title><source>Journal of Clinical Investigation</source><volume>118</volume><fpage>2200</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1172/JCI34725</pub-id><pub-id pub-id-type="pmid">18497887</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titone</surname> <given-names>D</given-names></name><name><surname>Ditman</surname> <given-names>T</given-names></name><name><surname>Holzman</surname> <given-names>PS</given-names></name><name><surname>Eichenbaum</surname> <given-names>H</given-names></name><name><surname>Levy</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Transitive inference in schizophrenia: impairments in relational memory organization</article-title><source>Schizophrenia Research</source><volume>68</volume><fpage>235</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(03)00152-X</pub-id><pub-id pub-id-type="pmid">15099606</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigo</surname> <given-names>D</given-names></name><name><surname>Thornicroft</surname> <given-names>G</given-names></name><name><surname>Atun</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Estimating the true global burden of mental illness</article-title><source>The Lancet Psychiatry</source><volume>3</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(15)00505-2</pub-id><pub-id pub-id-type="pmid">26851330</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vithayathil</surname> <given-names>J</given-names></name><name><surname>Pucilowska</surname> <given-names>J</given-names></name><name><surname>Landreth</surname> <given-names>GE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ERK/MAPK signaling and autism spectrum disorders</article-title><source>Progress in Brain Research</source><volume>241</volume><fpage>63</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2018.09.008</pub-id><pub-id pub-id-type="pmid">30447757</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>BF</given-names></name><name><surname>Zhang</surname> <given-names>TT</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Zou</surname> <given-names>XY</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>GQ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Impaired spatial learning is associated with disrupted integrity of the white matter in Akt3 knockout mice</article-title><source>CNS Neuroscience &amp; Therapeutics</source><volume>23</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/cns.12647</pub-id><pub-id pub-id-type="pmid">27671373</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissman</surname> <given-names>MM</given-names></name><name><surname>Bland</surname> <given-names>R</given-names></name><name><surname>Joyce</surname> <given-names>PR</given-names></name><name><surname>Newman</surname> <given-names>S</given-names></name><name><surname>Wells</surname> <given-names>JE</given-names></name><name><surname>Wittchen</surname> <given-names>HU</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Sex differences in rates of depression: cross-national perspectives</article-title><source>Journal of Affective Disorders</source><volume>29</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0165-0327(93)90025-F</pub-id><pub-id pub-id-type="pmid">8300980</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittchen</surname> <given-names>HU</given-names></name><name><surname>Jacobi</surname> <given-names>F</given-names></name><name><surname>Rehm</surname> <given-names>J</given-names></name><name><surname>Gustavsson</surname> <given-names>A</given-names></name><name><surname>Svensson</surname> <given-names>M</given-names></name><name><surname>Jönsson</surname> <given-names>B</given-names></name><name><surname>Olesen</surname> <given-names>J</given-names></name><name><surname>Allgulander</surname> <given-names>C</given-names></name><name><surname>Alonso</surname> <given-names>J</given-names></name><name><surname>Faravelli</surname> <given-names>C</given-names></name><name><surname>Fratiglioni</surname> <given-names>L</given-names></name><name><surname>Jennum</surname> <given-names>P</given-names></name><name><surname>Lieb</surname> <given-names>R</given-names></name><name><surname>Maercker</surname> <given-names>A</given-names></name><name><surname>van Os</surname> <given-names>J</given-names></name><name><surname>Preisig</surname> <given-names>M</given-names></name><name><surname>Salvador-Carulla</surname> <given-names>L</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name><name><surname>Steinhausen</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The size and burden of mental disorders and other disorders of the brain in Europe 2010</article-title><source>European Neuropsychopharmacology</source><volume>21</volume><fpage>655</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2011.07.018</pub-id><pub-id pub-id-type="pmid">21896369</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolthusen</surname> <given-names>RP</given-names></name><name><surname>Hass</surname> <given-names>J</given-names></name><name><surname>Walton</surname> <given-names>E</given-names></name><name><surname>Turner</surname> <given-names>JA</given-names></name><name><surname>Rössner</surname> <given-names>V</given-names></name><name><surname>Sponheim</surname> <given-names>SR</given-names></name><name><surname>Ho</surname> <given-names>BC</given-names></name><name><surname>Holt</surname> <given-names>DJ</given-names></name><name><surname>Gollub</surname> <given-names>RL</given-names></name><name><surname>Calhoun</surname> <given-names>V</given-names></name><name><surname>Ehrlich</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic underpinnings of left superior temporal gyrus thickness in patients with schizophrenia</article-title><source>The World Journal of Biological Psychiatry</source><volume>1</volume><fpage>430</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.3109/15622975.2015.1062915</pub-id><pub-id pub-id-type="pmid">26249676</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>H</given-names></name><name><surname>Levenga</surname> <given-names>J</given-names></name><name><surname>Cain</surname> <given-names>P</given-names></name><name><surname>Rothermel</surname> <given-names>B</given-names></name><name><surname>Klann</surname> <given-names>E</given-names></name><name><surname>Hoeffer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease</article-title><source>Acta Neuropathologica</source><volume>130</volume><fpage>829</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1499-8</pub-id><pub-id pub-id-type="pmid">26497675</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>MQ</given-names></name><name><surname>Xing</surname> <given-names>QH</given-names></name><name><surname>Zheng</surname> <given-names>YL</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>JJ</given-names></name><name><surname>He</surname> <given-names>G</given-names></name><name><surname>Guo</surname> <given-names>TW</given-names></name><name><surname>Feng</surname> <given-names>GY</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>He</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the chinese population</article-title><source>The Journal of Clinical Psychiatry</source><volume>68</volume><fpage>1358</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.4088/jcp.v68n0906</pub-id><pub-id pub-id-type="pmid">17915974</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonkers</surname> <given-names>KA</given-names></name><name><surname>Bruce</surname> <given-names>SE</given-names></name><name><surname>Dyck</surname> <given-names>IR</given-names></name><name><surname>Keller</surname> <given-names>MB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Chronicity, relapse, and illness?course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women from 8 years of follow-up</article-title><source>Depression and Anxiety</source><volume>17</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/da.10106</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>York</surname> <given-names>RD</given-names></name><name><surname>Molliver</surname> <given-names>DC</given-names></name><name><surname>Grewal</surname> <given-names>SS</given-names></name><name><surname>Stenberg</surname> <given-names>PE</given-names></name><name><surname>McCleskey</surname> <given-names>EW</given-names></name><name><surname>Stork</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via ras and Rap1</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>8069</fpage><lpage>8083</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.21.8069-8083.2000</pub-id><pub-id pub-id-type="pmid">11027277</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisel</surname> <given-names>A</given-names></name><name><surname>Munoz-Manchado</surname> <given-names>AB</given-names></name><name><surname>Codeluppi</surname> <given-names>S</given-names></name><name><surname>Lonnerberg</surname> <given-names>P</given-names></name><name><surname>La Manno</surname> <given-names>G</given-names></name><name><surname>Jureus</surname> <given-names>A</given-names></name><name><surname>Marques</surname> <given-names>S</given-names></name><name><surname>Munguba</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Rolny</surname> <given-names>C</given-names></name><name><surname>Castelo-Branco</surname> <given-names>G</given-names></name><name><surname>Hjerling-Leffler</surname> <given-names>J</given-names></name><name><surname>Linnarsson</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq</article-title><source>Science</source><volume>347</volume><fpage>1138</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1934</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56630.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lobo</surname><given-names>Mary Kay</given-names></name><role>Reviewing Editor</role><aff><institution>University of Maryland</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The role of molecular isoforms, highly similar molecules, in behaviors relevant to psychiatric disorders are not well elucidated. Using a series of genetic and behavioral approaches this research uncovers a new role for sex-specific contributions of molecular isoforms in distinct behaviors related to memory, anxiety, or fear. These findings have implications for understanding molecular mechanisms relevant to biological sex that occur in neuropsychiatric related behaviors.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction related to psychiatric disorders&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kate Wassum as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is 'in revision at <italic>eLife</italic>'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>This study examines AKT isoform-dependent effects on behaviors that are relevant to complex brain diseases. The study reveals differential selection of AKT1, AKT2, and AKT3 isoforms as a novel mechanism underlying anxiety, memory formation, and extinction. The authors further demonstrate that different AKT isoforms can compensate for each other, partially explaining the presence of very mild or null phenotypes. Overall, the manuscript expands upon the current limited knowledge of AKT signaling in maladaptive behaviors.</p><p>Essential revisions:</p><p>1) A concern with this study is that the results do not present a coherent conclusion, thus, it is not clear what is learned from this study. Please reshape the Introduction to clearly motivate the rationale to study these specific isoforms of AKT with genetic deletion, and what relevance this has for specific psychiatric disease and why the behavioral test performed are relevant. Additional comments below should also be integrated into this revised Introduction.</p><p>2) In the Introduction, and some parts of the Discussion, the authors indicate that AKT is associated with MDD, and that antidepressant medications, among other psychotropic agents, modify AKT signaling. Yet, the authors provide only one reference that supports such statement for antipsychotics only (Beaulieu et al., 2008). Please reference other sources to fully support such statements across the paper, particularly for antidepressants in human subjects (for example, Krishnan et al., 2008).</p><p>3) The NIH released a statement on the use of animals for research on psychiatric illness (https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-053.html). The statement emphasizes the importance of wording (including &quot;of&quot; versus &quot;for&quot;) in descriptions and interpretations of the types of studies described in the present article. It would seem critical to ensure that the conceptualizations of genetically altered mice, and the behaviors they exhibit when compared to wildtypes, are made in the context of &quot;modeling&quot; endpoints that are suggestive of symptoms that underlie human psychiatric illnesses. Thus, it is imperative that the assertions in the present article are consistent with this NIH statement. As one example, the insinuation that the behaviors described (e.g., OFA, EPM, MWM, fear conditioning/extinction) can accurately assess neuropsychiatric behavior in a mouse (i.e., last paragraph of Introduction) may be viewed as increasingly unacceptable. Therefore, please revise to describe these tests in terms of their objective endpoints.</p><p>4) Following the previous point, at the end of the Introduction, the authors indicate that their &quot;findings have significant implications for diagnoses and therapies.&quot; Please describe how this statement is consistent with the NIH considerations regarding the use of animal neurobehavioral approaches in basic studies.</p><p>5) One of prominent phenotypes in the study is a male-specific enhanced fear extinction in AKT1 KO. This can also be reversed by expressing AKT1 in the PFC. However, one of the main brain parts responsible for fear extinction is the amygdala and there are studies showing the connection between the PFC and amygdala may also play role in fear extinction. In addition, in Figure 6, conditional KO of AKT1 show normal extinction, which is possibly due to the fact that the cre line used in the study has not reported to have expression in the amygdala. This suggests AKT1 in the amygdala plays a role in fear extinction. Please examine whether AKT1 expression in the amygdala of KO mice can reverse fear extinction, or test whether specific loss of AKT1 in the amygdala (by viral shRNA knockdown in WT mice) has any effects on behavior.</p><p>6) The authors inject AKT1 into the Prelimbic cortex (PL), which is sufficient to reverse altered fear extinction in KO mice. Importantly, several studies show that the connection between the amygdala and PL mediates fear acquisition and retrieval while the link between the amygdala and infralimbic cortex (IL) are thought to mediate fear extinction (Choi et al., PNAS. 2010. and Laurent et al., Learning and Memory. 2009). Please explain how AKT1 expression in the PL can reverse fear extinction or examine the effects of AKT1 expression in the IL on fear extinction in KO animals.</p><p>Please also include a representative example of expression with sufficient display of anatomical landmarks to indicate that expression was restricted to the PL, as well as a schematic of expression spread overlaid for each subject so readers can see the extent of expression for the entire cohort.</p><p>7) Across the manuscript, the authors indicate that their findings are &quot;sex-dependent.&quot; This is technically inaccurate, given that sex was not incorporated as an independent variable in their statistical analyses. This is particularly problematic in the Discussion section of the paper, since the experimental design does not support such inferences. A similar problem is exhibited for the arguments made across the different AKT isoforms (AKT1, AKT2, AKT3), since &quot;isoform&quot; was also not incorporated as an independent variable. The data should be re-analyzed using a 2-way ANOVA with &quot;sex&quot; and &quot;AKT isoform&quot; as sources of variance. Please also include a discussion on potential sex-dependent downstream players.</p><p>8) In the Experimental Design and Statistical analysis section of the paper, the authors indicate that outliers were excluded from the study. The specific number of excluded animals, across each experiment, should be clearly indicated. Also, the current manuscript only includes group numbers. The total number (n) of animals per experimental group needs to be included (a table depicting this information would be helpful, or adding the &quot;n&quot; within each group in the data figures). This is particularly important, given that the degrees of freedom change across experiments (this is confusing, since the authors indicate that mice were used across all experiments).</p><p>Because the numbers of animals differ considerable between some of the groups, please also show that the data meet the assumption of homogeneity of variance for ANOVA.</p><p>9) In Figure 6, please confirm loss of AKT1 expression by immunohistochemistry to examine the brain regions with AKT1 loss of expression.</p><p>10) Given the complexity and length of the behavioral tests, it would be very useful if the authors included a schematic representation of the experimental timeline, depicting the multiple groups of AKT mutants, the rescue experiment, and the timeline of the behavioral tests.</p><p>11) While the authors use a genetically targeted approach to study AKT isoforms, these molecules cross-talk with many signaling pathways. Therefore, it is very likely that multiple pathways are de-regulated by AKT KO. Assessing activation of other cross-talk signaling molecules (PI3-kinase, GSK3b, ERK, or CREB) across the multiple AKT mutants (Western blotting) would provide a better understanding of the role that each AKT isoform plays in the AKT-dependent behavioral modifications.</p><p>12) Some of the AKT KO mouse lines have previously been shown to be smaller and display growth deficiency (i.e., Dummler et al., 2006-DOI: 10.1128/MCB.00722-06; Cho et al., 2001-DOI: 10.1074/jbc.C100462200). Are the same lines used in the current study. Are the mice smaller? Did the authors check the general health state of the mice? It is suggested is to add a short paragraph in the manuscript that clarifies this point.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction related to psychiatric disorders&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Kate Wassum (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>1) The authors conclude that AKT1 in PFC interneurons is important for fear extinction. They showed that virally expressed AKT1 in the PFC reversed enhanced fear extinction in KO mice (Figure 5). However, the study lacks confirmation of AKT1 expression in interneurons. The authors are able to show double labeling of PV and AKT1 in the PFC in Figure 6—figure supplement 1. Thus, the authors should be able to perform similar labeling to demonstrate that virally expressed AKT1 is present in PFC interneurons in Figure 5C to confirm that AKT1 is indeed expressed in PFC interneurons of KO mice.</p><p>2) Describing sex as an &quot;experimental variable&quot; throughout the manuscripts is inaccurate. The authors are to be commended for including both males and females in their work, and indeed, the inclusion of both sexes is extremely important. But not including sex as an independent variable in their statistical analyses (ANOVAs), precludes the authors from suggesting that sex was an experimental variable (this is misleading, and technically incorrect). There is agreement with the justification provided by the authors for not including sex or isoform as a variable in their statistical approaches. For this reason, it is encouraged that the authors remove any statement indicating that their findings are isoform or sex &quot;dependent&quot;, and simply rephrase them as sex and isoform-&quot;specific&quot; (because data is compared to a same sex control).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56630.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) A concern with this study is that the results do not present a coherent conclusion, thus, it is not clear what is learned from this study. Please reshape the Introduction to clearly motivate the rationale to study these specific isoforms of AKT with genetic deletion, and what relevance this has for specific psychiatric disease and why the behavioral test performed are relevant. Additional comments below should also be integrated into this revised Introduction.</p></disp-quote><p>To address the reviewers’ concerns on this important point we have revised the Introduction as well as the Significance Statement to reflect more clearly the goals and knowledge gaps that motivated these studies. AKT has been implicated in neuropsychiatric disorders from human studies but it is a central kinase in many cellular signaling pathways, so understanding the specificity of AKT activity will be important for improving diagnosis and therapeutic interventions. Our study investigated the isoform- and sex-specific functions of AKT in mouse behaviors with underlying neural circuits and activity that may model brain processes impacted in neuropsychiatric disorders. The use of genetic deletion is a standard approach for understanding the contributions of a gene toward a process of interest. While there are other approaches (e.g. gain of function, expression of allelic variants), these approaches are not currently available for mouse model work without additional reagent generation. We did use the approach of conditional cell type-specific <italic>Akt</italic> isoform removal and viral-mediated gene expression to extend our results beyond null characterization and feel that these studies are very informative above and beyond what is known about AKT function in the context of behavior and how these behaviors may relate to human neuropsychiatric disorder.</p><disp-quote content-type="editor-comment"><p>2) In the Introduction, and some parts of the Discussion, the authors indicate that AKT is associated with MDD, and that antidepressant medications, among other psychotropic agents, modify AKT signaling. Yet, the authors provide only one reference that supports such statement for antipsychotics only (Beaulieu et al., 2008). Please reference other sources to fully support such statements across the paper, particularly for antidepressants in human subjects (for example, Krishnan et al., 2008).</p></disp-quote><p>As suggested by the reviewers, we have included more references for AKT’s involvement in psychotropic agents, including antidepressants. These additional references add to the growing significance of the AKT signaling pathway in psychiatric disorders.</p><disp-quote content-type="editor-comment"><p>3) The NIH released a statement on the use of animals for research on psychiatric illness (https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-053.html). The statement emphasizes the importance of wording (including &quot;of&quot; versus &quot;for&quot;) in descriptions and interpretations of the types of studies described in the present article. It would seem critical to ensure that the conceptualizations of genetically altered mice, and the behaviors they exhibit when compared to wildtypes, are made in the context of &quot;modeling&quot; endpoints that are suggestive of symptoms that underlie human psychiatric illnesses. Thus, it is imperative that the assertions in the present article are consistent with this NIH statement. As one example, the insinuation that the behaviors described (e.g., OFA, EPM, MWM, fear conditioning/extinction) can accurately assess neuropsychiatric behavior in a mouse (i.e., last paragraph of Introduction) may be viewed as increasingly unacceptable. Therefore, please revise to describe these tests in terms of their objective endpoints.</p></disp-quote><p>We understand that the behavioral measures we assessed in mice are endpoints which serve as models for examining effects on neural activity relevant to brain functions affected in psychiatric disorders and apologize for inadvertently using language that was not responsive to the NIH statement and guidance. We have revised the Introduction and wording in other places of the manuscript to be more objective and amenable to NOT-MH-19-053. The goals of our research were to identify behaviors and neurobiological processes impacted by AKT isoform activity and to examine them in the context of potential sex differences, which had been largely overlooked in previous preclinical studies. This has been more clearly delineated in the text.</p><disp-quote content-type="editor-comment"><p>4) Following the previous point, at the end of the Introduction, the authors indicate that their &quot;findings have significant implications for diagnoses and therapies.&quot; Please describe how this statement is consistent with the NIH considerations regarding the use of animal neurobehavioral approaches in basic studies.</p></disp-quote><p>We have modified the Introduction to better fit the guidelines outlined in NOT-MH-19-053. In accordance with this notice, our study highlights the findings in the context of behavioral assays as readouts “for” brain function that may model neurobiological processes involved in psychiatric disorders. We delineate the contributions of AKT isoforms to specific brain processes (e.g. hippocampus-dependent long-term memory formation) and identify sex-dependent differences in the requirements for AKT activity.</p><disp-quote content-type="editor-comment"><p>5) One of prominent phenotypes in the study is a male-specific enhanced fear extinction in AKT1 KO. This can also be reversed by expressing AKT1 in the PFC. However, one of the main brain parts responsible for fear extinction is the amygdala and there are studies showing the connection between the PFC and amygdala may also play role in fear extinction. In addition, in Figure 6, conditional KO of AKT1 show normal extinction, which is possibly due to the fact that the cre line used in the study has not reported to have expression in the amygdala. This suggests AKT1 in the amygdala plays a role in fear extinction. Please examine whether AKT1 expression in the amygdala of KO mice can reverse fear extinction, or test whether specific loss of AKT1 in the amygdala (by viral shRNA knockdown in WT mice) has any effects on behavior.</p></disp-quote><p>The particular Cre line used for this study, T29-1 (Tsien et al., 1996), does in fact express quite well in the amygdala. In a previous report, we confirmed its expression in the amygdala (Hoeffer et al., 2008, Figure 1). To provide additional support, we have included immunoblotting and histological data confirming reduced AKT1 expression in the amygdala as well as in the PFC of conditional <italic>Akt1</italic> KO (<italic>cAkt1</italic> KO) mice driven by the T29-1 line (Figure 6—figure supplement 1). We show further that this line expresses in excitatory neurons and not interneurons of the amygdala and PFC (Figure 6—figure supplement 1). Taken together with our finding that neuronal AKT1 expression in the PFC of <italic>Akt1</italic> KO mice reverses their fear extinction phenotype, these data suggest that interneuronal AKT1 in the PFC plays a critical role in fear extinction. Therefore, <italic>cAkt1</italic> KO mice showed normal extinction possibly because AKT1 expression remained intact in interneurons of the PFC. We do not dispute the important role of the amygdala in extinction, but our data indicate that AKT1 is not required in excitatory neuronal populations of the amygdala or PFC for the normal display of extinction. To more thoroughly test this idea, we plan to generate interneuron-specific <italic>Akt1</italic> KO mice and examine fear extinction in these animals for future studies. We have included this discussion in the revised manuscript. Based on these data, we did not pursue behavioral studies to test the role of AKT1 specifically in the amygdala, although we agree that it would be interesting to examine as part of a larger future study of brain region-specific AKT1 functions.</p><disp-quote content-type="editor-comment"><p>6) The authors inject AKT1 into the Prelimbic cortex (PL), which is sufficient to reverse altered fear extinction in KO mice. Importantly, several studies show that the connection between the amygdala and PL mediates fear acquisition and retrieval while the link between the amygdala and infralimbic cortex (IL) are thought to mediate fear extinction (Choi et al., PNAS. 2010. and Laurent et al., Learning and Memory. 2009). Please explain how AKT1 expression in the PL can reverse fear extinction or examine the effects of AKT1 expression in the IL on fear extinction in KO animals.</p><p>Please also include a representative example of expression with sufficient display of anatomical landmarks to indicate that expression was restricted to the PL, as well as a schematic of expression spread overlaid for each subject so readers can see the extent of expression for the entire cohort.</p></disp-quote><p>We apologize that the methods for viral-mediated AKT1 expression was not clearly described in the original submission. Although we targeted the PL region of the medial prefrontal cortex (mPFC), it was not our intention to imply that viral expression was limited to the PL. At the reviewers’ suggestion, we provide a representative example of AAV expression in the PFC along with a schematic of the expression spread overlaid for available subjects, which we have incorporated into Figure 5. While AAV expression was visually confirmed for every subject, we had only comprehensively imaged a few representative samples. As these experiments were performed over the course of a couple years, the original slides for confirming expression were no longer usable for imaging. We prepared new slides but only some subjects had brain sections with PFC available. To construct the schematic, we compiled images from this subset, which consists of samples from each group. The revised figure shows that both the PL and IL exhibit AAV expression (Figure 5B). We do not distinguish between the requirements for AKT1 activity in PL or IL in this study. Instead, we elected for a more general approach, indeed given some conflicting reports regarding the requirement for the PL and IL in fear extinction processes (Do-Monte et al., 2015; Sierra-Mercado et al., 2011; Marek et al., 2018). Our simplest interpretation of the results from restoring AKT1 expression in the mPFC of <italic>Akt1</italic> KO mice is that AKT1 activity is normally required in the mPFC to limit extinction learning. While examining the role of AKT1 activity in specific PFC regions would be an interesting line of inquiry, based on our results from forebrain excitatory neuron-specific removal of AKT1, we posit that the AKT1 activity utilized during extinction learning is primarily required in interneuronal populations of the PFC (Figure 6 and Figure 6—figure supplement 1). The AAV-AKT1 construct we used expresses in cells responsive to the synapsin promoter, so it does not resolve AKT1 activity in excitatory or inhibitory neurons (Figure 5). Therefore, as mentioned for point #5, our future efforts will directly test the idea that interneuronal AKT1 is responsible for normal extinction behavior using genetic approaches to eliminate AKT1 and AAV constructs designed to limit AKT1 expression to interneurons.</p><disp-quote content-type="editor-comment"><p>7) Across the manuscript, the authors indicate that their findings are &quot;sex-dependent.&quot; This is technically inaccurate, given that sex was not incorporated as an independent variable in their statistical analyses. This is particularly problematic in the Discussion section of the paper, since the experimental design does not support such inferences. A similar problem is exhibited for the arguments made across the different AKT isoforms (AKT1, AKT2, AKT3), since &quot;isoform&quot; was also not incorporated as an independent variable. The data should be re-analyzed using a 2-way ANOVA with &quot;sex&quot; and &quot;AKT isoform&quot; as sources of variance. Please also include a discussion on potential sex-dependent downstream players.</p></disp-quote><p>This is a very important point, and we carefully considered the implications of our research design and interpretations to address this critique. It appears to us that many labs employ a variety of statistical approaches, some applied correctly, some applied incorrectly. It is also the case that there are often multiple statistical approaches that could be used, and if the “take-home” message doesn’t change it can simply be a matter of preference. The two main issues raised by reviewers for this manuscript focus on how to handle possible sex differences and whether to examine possible <italic>Akt</italic> isoform differences. Below we present our rationale for the way we conducted the analyses.</p><p>1) Sex differences: We do not share the reviewers’ interpretation about the use of “sex-dependent.” Behavioral effects observed in one sex but not another is sex-dependent. However, we understand the concept of including sex as a variable in our statistical analyses. In a previous submission to another journal that included only a subset of these data, we did in fact prepare our manuscript with two-way ANOVA analyses (genotype and sex) but received criticisms about that approach. In that case, the reviewers requested post-hoc analyses, but post-hoc tests are not appropriate when there are only two levels for each variable (e.g. genotype can be only KO/WT and sex can be only M/F). Therefore, we consulted with local biostatistical experts (Dr. Luke Evans and Dr. Marissa Ehringer) and revised our figures based on their directions.</p><p>Dr. Ehringer deals with this sex effect issue on a regular basis because there are well-known sex differences in both rodents and humans for alcohol-related behaviors, which is a major area of her research. Given the <italic>a priori</italic> knowledge of such sex differences (Choleris et al., 2018; Andreano and Cahill, 2009; Wiltgen et al., 2005; File, 2001), analyses are frequently performed separately by sex to simplify the presentation and interpretation of results. It is not uncommon for researchers to actually submit two different papers, one for each sex. In our case, the behaviors we examined are also well-known to show reproducible sex differences in WT (C57BL/6) strains (Archer, 1977; Wiltgen et al., 2001; Bolivar et al., 2001; Voikar et al., 2001; La Buda et al., 2002; Gresack and Frick, 2003; Guo et al., 2004; Berger-Sweeney et al., 2005; Jonasson, 2005; Calderone et al., 2008; An et al., 2011; Davis et al., 2012; Matsuda et al., 2015; Arakawa, 2019). Thus, to avoid complicating the current submission with results of behavioral differences inherent to sex alone, which are already known, and because males and females within each genotype set were tested separately, we opted to perform within-sex t-tests (except for Figure 5, in which the independent variable had three levels). This analysis facilitated presentation of our results for easy comparison between WT and KO genotypes within either male or female groups. It allowed us to show data normalized to WT controls within each sex in order to focus on the effect of <italic>Akt</italic> isoform manipulation, which was the primary goal of our study. At the reviewers’ suggestion, we also performed two-way ANOVA, and the overall “take-home” message does not change. This analysis is included in Table 4. If all reviewers and the editor strongly feel we should present the results as a two-way ANOVA, we can change our figures. Based on our previous submission experience, we expect this might cause more confusion than the simpler t-test, which we believe is justified based on previously known sex differences and the experimental design.</p><p>2) AKT isoform comparisons: We believe including <italic>Akt</italic> isoform as an independent variable for analyses is not appropriate for four reasons. First, the individual <italic>Akt</italic> mutant lines are bred and maintained separately. They cannot be reasonably grouped all together because they are maintained on different backgrounds and not simply interchangeable. In order to analyze the data as proposed (all <italic>Akt</italic> mutants simultaneously), all the mutant <italic>Akt</italic> alleles would have to be maintained in the same strain. This was not done for practical reasons; it would require thousands of progeny from <italic>Akt1</italic><bold><sup>+/-</sup></bold><italic>Akt2</italic><bold><sup>+/-</sup></bold><italic>Akt3</italic><bold><sup>+/-</sup></bold> breeder mice to complete these studies in this way and only 1.6% of mice derived from such a cross would be either pure WT or KO for each isoform group. Second, although all the mice are maintained on a C57Bl/6 background, the different <italic>Akt</italic> lines are not isogenic. We regularly introduce new C57Bl/6 mice into all our strains to prevent the accumulation of genetic modifiers. Despite this precaution, “WT” mice from each strain demonstrate slight performance differences in some tasks compared with “WT” mice from other <italic>Akt</italic> isoform strains. There are many possible reasons for this (genetics, rearing, microbiome differences, etc.) but those factors are largely beyond our control. Therefore, it would not be scientifically appropriate to compare KO mice to “WT” mice from a different line or to create a master “WT” group by simply averaging the performance of WT mice from all lines. Third, we used littermates obtained from breeding the individual <italic>Akt</italic> lines for each experimental group, a practice that is supported by previous studies (Holmdahl and Malissen, 2012). This important element of rigorous experimental design would be lost if we were to combine across all isoform groups. Finally, the experiments in this study were not designed or performed with the goal of comparing each <italic>Akt</italic> mutant line to one other. Combining all the mutants for simultaneous comparison creates an insurmountable multiple comparison problem that would necessitate testing many more animals, as the power analyses used to design our experiments were based on separate isoform testing. Another way to view the situation is that because the experiments were performed with only one mutant at a time, it would have been reasonable and appropriate to prepare three different manuscripts, one for each isoform, which would be analyzed independently.</p><p>At the reviewers’ request, we also included in the revised manuscript a discussion on potential sex-dependent downstream players, which incorporates the findings from our experiments to address point #11 below.</p><disp-quote content-type="editor-comment"><p>8) In the Experimental Design and Statistical analysis section of the paper, the authors indicate that outliers were excluded from the study. The specific number of excluded animals, across each experiment, should be clearly indicated. Also, the current manuscript only includes group numbers. The total number (n) of animals per experimental group needs to be included (a table depicting this information would be helpful, or adding the &quot;n&quot; within each group in the data figures). This is particularly important, given that the degrees of freedom change across experiments (this is confusing, since the authors indicate that mice were used across all experiments).</p><p>Because the numbers of animals differ considerable between some of the groups, please also show that the data meet the assumption of homogeneity of variance for ANOVA.</p></disp-quote><p>We apologize that presentation of the experimental details for our statistical analysis was confusing in the original submission. We have now added summary tables with the number of animals per experimental group (also included in the figure legends), number of excluded animals and reason for exclusion, and homogeneity of variance test results across each experiment (Tables 2-4).</p><disp-quote content-type="editor-comment"><p>9) In Figure 6, please confirm loss of AKT1 expression by immunohistochemistry to examine the brain regions with AKT1 loss of expression.</p></disp-quote><p>We previously confirmed that conditional <italic>Akt1</italic> removal under the T29-1 <italic>Camk2α-</italic>Cre driver reduced AKT1 expression in the hippocampus (Levenga et al., 2017). Complementing this report, we now demonstrate using western blotting and immunohistochemistry that AKT1 expression is also reduced in the amygdala and PFC. These data have been added as a supplemental figure (Figure 6—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>10) Given the complexity and length of the behavioral tests, it would be very useful if the authors included a schematic representation of the experimental timeline, depicting the multiple groups of AKT mutants, the rescue experiment, and the timeline of the behavioral tests.</p></disp-quote><p>We thank the reviewers for this very useful suggestion and have amended our Materials and methods section to include a flowchart for the behavioral assays (Figure 1—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>11) While the authors use a genetically targeted approach to study AKT isoforms, these molecules cross-talk with many signaling pathways. Therefore, it is very likely that multiple pathways are de-regulated by AKT KO. Assessing activation of other cross-talk signaling molecules (PI3-kinase, GSK3b, ERK, or CREB) across the multiple AKT mutants (Western blotting) would provide a better understanding of the role that each AKT isoform plays in the AKT-dependent behavioral modifications.</p></disp-quote><p>We agree that loss of AKT likely influences many different signaling pathways and that these may be involved in the behavioral effects we observed. Following the reviewers’ suggestion, we performed western blot analysis of PDK1, GSK3β, and ERK activation to assess candidate signaling upstream, downstream, and parallel of AKT, respectively, in brain tissue from <italic>Akt</italic> isoform mutants of both sexes. These data are now included as Figure 9 and associated supplemental figures. While we did not identify many differences in this analysis, we did find some exciting isoform- and sex-dependent effects on GSK3β phosphorylation. We hope to investigate other potential signaling differences that may mediate the behavioral effects of <italic>Akt</italic> isoform deficiency using a more comprehensive approach, such as mass spectrometry, in a follow-up study.</p><disp-quote content-type="editor-comment"><p>12) Some of the AKT KO mouse lines have previously been shown to be smaller and display growth deficiency (i.e., Dummler et al., 2006-DOI: 10.1128/MCB.00722-06; Cho et al., 2001-DOI: 10.1074/jbc.C100462200). Are the same lines used in the current study. Are the mice smaller? Did the authors check the general health state of the mice? It is suggested is to add a short paragraph in the manuscript that clarifies this point.</p></disp-quote><p>We obtained our <italic>Akt1</italic> and <italic>Akt2</italic> KO lines from JAX, donated by Morris Birnbaum. Our <italic>Akt3</italic> KO line was also obtained from the Birnbaum Lab by direct request and is not the same strain described in Dummler et al. 2006. This information has been added to the Key Resources Table. In our hands, both <italic>Akt1</italic> and <italic>Akt3</italic> KO mice show significantly reduced sizes compared with their WT littermates. The size reduction is slight in <italic>Akt1</italic> KO mice and more pronounced in <italic>Akt3</italic> KO mice, consistent with previous reports (Cho et al., 2001a (PMID: 11533044); Easton et al., 2005). There are conflicting reports of <italic>Akt2</italic> KO mice having a reduced weight (Cho et al., 2001b (PMID: 11387480); Garofalo et al., 2003). In our hands, <italic>Akt2</italic> KO mice trend towards a reduced size but the difference is not significant. <italic>Akt2</italic> KO mice do develop insulinemia that becomes progressively worse with age (Cho et al., 2001b; Garofalo et al., 2003). Most glucose-related phenotypes in <italic>Akt2</italic> KO mice are uncovered following fasting or with aging, but our mice have access to food <italic>ad libitum</italic> and were tested younger than 16 weeks, before insulin-related phenotypes become severe. Previous studies examined the general health of all these KO mice, and apart from size, found them generally indistinguishable from their WT littermates (Cho et al., 2001a; Cho et al., 2001b; Easton et al., 2005). In addition, we assessed sensory functions (acoustic startle, vision, and pain perception) and found no differences between KO and WT mice. Locomotor assessments, such as distance moved and swim velocity, were included in our behavioral assays to rule out locomotor defects as a potential confound for observed behavioral differences. None were identified. Some of these control data are included in the submitted figures (e.g. distance moved, visual platform performance, baseline freezing). We have added a paragraph about general health to the Materials and methods section to make clear this point.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>1) The authors conclude that AKT1 in PFC interneurons is important for fear extinction. They showed that virally expressed AKT1 in the PFC reversed enhanced fear extinction in KO mice (Figure 5). However, the study lacks confirmation of AKT1 expression in interneurons. The authors are able to show double labeling of PV and AKT1 in the PFC in Figure 6—figure supplement 1. Thus, the authors should be able to perform similar labeling to demonstrate that virally expressed AKT1 is present in PFC interneurons in Figure 5C to confirm that AKT1 is indeed expressed in PFC interneurons of KO mice.</p></disp-quote><p>As suggested, we now include images confirming that virally expressed AKT1 in the PFC of <italic>Akt1</italic> KO mice is present in interneurons with our AAV construct (Figure 5—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>2) Describing sex as an &quot;experimental variable&quot; throughout the manuscripts is inaccurate. The authors are to be commended for including both males and females in their work, and indeed, the inclusion of both sexes is extremely important. But not including sex as an independent variable in their statistical analyses (ANOVAs), precludes the authors from suggesting that sex was an experimental variable (this is misleading, and technically incorrect). There is agreement with the justification provided by the authors for not including sex or isoform as a variable in their statistical approaches. For this reason, it is encouraged that the authors remove any statement indicating that their findings are isoform or sex &quot;dependent&quot;, and simply rephrase them as sex and isoform-&quot;specific&quot; (because data is compared to a same sex control).</p></disp-quote><p>We have changed references of “dependent” to “specific” throughout the text.</p></body></sub-article></article>